

ANTHONY NOLAN

ANNUAL REPORT AND ACCOUNTS
2018/19

FOR THE YEAR ENDED 31 MARCH 2019



STAFF, SUPPORTERS AND ADDRESS LIST

PATRON

Olivia Colman CBE
(from 18.7.18)

BOARD OF TRUSTEES

Chair

Ian Krieger*

Vice Chair

Carol MacKinnon (from 18.1.19)

Life President

Simon Dyson MBE

Chair of the Audit and Finance Committee

Carol MacKinnon

TRUSTEES

Dr Peter Aitken

Mike Altendorf

Fran Burke (retired 29.11.18)

Lionel Cashin

Dr Chonnettia Jones

Dr James Kustow

Carol MacKinnon*

Dr Ann Robinson

Peter Robinson*

Simon Spyer

Brian Turner CBE

Olivier Zucker*

Martin Laws*

Professor Antonio Pagliuca (appointed 18.1.19)

Martin Ritson (appointed 18.1.19)

*Audit and Finance Committee member


MEDICAL ADVISOR

Professor Charles Craddock CBE

STRATEGIC LEADERSHIP TEAM

Chief Executive

Henny Braund



Engagement Director

Terence Lovell

Finance and Resources Director

Gareth Morgan

Chief Information Officer

Danny Attias

Operations and Patient Services Director

Nicola Alderson

Bioinformatics Director

Professor Steven Marsh

Scientific director of research

Professor Alejandro Madrigal

Clinical Histocompatibility and Immunogenetics Director

Dr Katy Latham

Medical Director

Dr Chloe Anthias

Company Secretary

Caroline Woollard

INDEPENDENT REVIEW BOARD FOR CELL & GENE THERAPIES**Chair**

Dr. Laura Machin – Senior Lecturer in Medical Ethics at Lancaster University

External Haematology Consultant

Dr. Victoria Potter – Haematology Consultant at King's College Hospital NHS Foundation Trust

PROFESSIONAL ADVISORS**Independent Auditors**

RSM UK Audit LLP

25 Farringdon Street
London EC4A 4AB

Bankers

Barclays Bank plc

1 Churchill Place
London E14 5HP

Solicitors

Bates, Wells and Braithwaite

10 Queen Street Place
London EC4R 1BE

Investment Manager

Smith & Williamson
Investment Management

25 Moorgate
London EC2R 6AY

ANTHONY NOLAN

Registered Office

Royal Free Hospital Pond Street, Hampstead London NW3 2QG

Administrative Address

2 Heathgate Place 75-87 Agincourt Road Hampstead London NW3 2NU 0303 303 0303

England And Wales Charity Registration Number

803716

Scotland Charity Registration Number

SC038827

Company Registration Number

02379280

CONTENTS

Chair And Chief Executive Statement	5
Lifesaving, Together	
Looking Forward	
The Year In Numbers	10
Trustees' Report	12
What We Do – Objectives And Activities	
Rupert And Billy's Story	14
Anthony Nolan Strategic Report – Achievements And Performance	15
What We've Achieved In 2018-19	
Strategic Aim One	18
Matching Patients And Donors	
Making The Best Possible Matches	
Recruiting Potential Lifesavers	
Supporting Patients	
Rinesh's Story	22
Strategic Aim Two	23
Collaborating With Partners	
Leading The Transplant Community	
Influencing Key Stakeholders	
Anthony Nolan Clinical Nurse Specialists Update	26
Strategic Aim Three	27
Increasing Awareness	
Raising Lifesaving Funds	
Looking After Our People	
Improving Efficiency And Effectiveness	
Kimberley's Story	32
Our Volunteers	33
Marrow's 20th Anniversary	34
Our Future	35
Together, We Can Save Lives	
Trustees' Report Continued	37
How We Operate – Structure, Governance And Management	
The Financial Review	43
Independent Auditors' Report	45
Consolidated Statements Of Financial Activities	50
Parent Charity Only Statement Of Financial Activities	51
Consolidated & Charity Balance Sheets	52
Consolidated & Charity Statements Of Cash Flow	53
Notes To The Financial Statements	54

LIFESAVING, TOGETHER

CHAIR AND CHIEF EXECUTIVE STATEMENT

At Anthony Nolan, our passionate supporters, volunteers and staff have been saving and improving the lives of people who need a stem cell transplant since 1974. In the 45 years since, we've learned that when we work together, we can do more for the patients who need us.

Every year in the UK, another 2,000 patients with blood cancer and blood disorders start their search to find a matching donor – a stem cell transplant is often their last chance of survival. Fundamentally, a match requires two people – two people who are uniquely connected, with one having the potential to save the other's life. This means our work is all about bringing people together.

We're here to make sure patients are not alone, help them find their matching donor and ensure they receive the ongoing support they need to both survive and have a good quality of life post-transplant. In the last 12 months alone, we've given 1,425 people with blood cancer and blood disorders a second chance of life – more than ever before.

We've come a long way since 1974 – today, our stem cell register sits alongside dedicated patient services, world-leading research, and policy expertise. Working together with patients and clinicians, we want to use our unique position to achieve even more for the people who need us.

And in the final year of our 2015-2018 Organisational Strategy, *Saving Lives: Achieving More*, we have achieved a great deal:

There were 732,549 on our stem cell register at the end of the financial year, all ready and waiting to save someone's life, and in June 2019 we reached the amazing milestone of three quarters of a million potential donors.

Through recruitment events and online promotion, we have recruited 74,115 more potential lifesavers aged 16-30. Our recruitment age is informed by our research which shows a definite link between younger donors and better survival rates. We have continued to target our efforts accordingly, in particular through our Hero Project work in schools and our Marrow groups in universities, which together have recruited over 23,000 potential donors.

We have also continued to expand and promote our Cord Blood Bank, to offer an alternative for patients who are unable to find a match on the register, and which now holds over 8,500 cord blood units.

We are very proud of the impact our pioneering research is having on patients' lives. This includes typing donors to a higher level to provide patients with the best possible match, as our recently published paper from our Patient/Donor project shows the value of higher level matching for improved survival and quality of life.

The IMPACT clinical trials network continues to go from strength to strength. Launched in 2017, this groundbreaking partnership jointly funded by Anthony Nolan, Leuka and NHS Blood and Transplant seeks to improve the outcomes of transplant patients through accelerated delivery of clinical trials across the UK. IMPACT is now recruiting patients to two much-needed studies, with another two trials approved.

Our Clinical Nurse Specialists (CNS) programme continues to expand around the country, giving patients the dedicated care they desperately need. We have now funded 12 CNS, as well as four new Clinical Psychologist posts to ensure transplant patients receive specific psychological support to improve their quality of life.

We are thrilled that Olivia Colman CBE is our patron. Olivia's Anthony Nolan Story featured in our film series, where she talked about her friend searching for a matching donor. We are

very grateful to Olivia for sharing this heartfelt story, and feel very fortunate to have such a talented and committed patron helping to inspire more support.

We are very proud of our achievements across the year, which have only been made possible by dedicated people, the right systems, and generous funding. In 2018-2019, through a combination of charitable gifts and incredible fundraising by our supporters and partners, we raised £9.7m.

A vital part of driving our work forward is ensuring this funding works as hard as possible to maximise the impact for patients. For every £1 we receive, 91p goes into saving lives, 8p into raising money and inspiring people to support us, and 1p into governance.

LOOKING FORWARD

CHAIR AND CHIEF EXECUTIVE STATEMENT continued

As well as looking back over the last year, we are excited to move forward with our new Organisational Strategy, *Together, We Can Save Lives*, as we aim to provide patients with the best possible treatment and the best possible care.

We owe it to future patients to be the leader and catalyst in improving stem cell transplant outcomes and exploring the potential of innovative treatments. Our new strategy marks a renewed determination to shape and contribute to scientific and technological advancements that will ultimately broaden our focus for the benefit of patients.

We are very excited for the first year of our new strategy, which is sure to be a busy one:

We have already begun a patient and public involvement (PPI) review to ensure that the experiences and medical needs of patients continually inform every aspect of our work and the services we provide.

Our new report, *A Pathway for Post-Transplant Care*, developed in collaboration with patients and healthcare professionals, was published in May 2019. Drawing on our evidence base and influencing position, the report sets out a minimum standard of care and support for transplant patients, for as long as necessary and no matter where they live. Our focus is now on working with partners across the UK, both nationally and locally, to understand how we can help make the pathway a reality.

Our Cell and Gene Therapies team will support the delivery of innovative treatments to save more lives and improve patient quality of life. We'll do this by collaborating with innovative researchers and harnessing our expertise, infrastructure and our unparalleled experience of facilitating stem cell transplants.

We will also be focusing on strengthening our foundations and enablers of change, so we are ready to do even more. We know there are times when the external environment is harder, or when things take longer than we thought, but by being prepared to respond to both the opportunities and challenges we face, we will continue to save and improve more lives.

We are further strengthening our open and collaborative working culture, ensuring it reflects our values as 'One Anthony Nolan'. To do this, we will invest in improving our infrastructure, capabilities and capacity, in particular through extensive investment in our technology, so that we have firm foundations to work from and to be fit for the future.

We're also pleased to share our new campaign film telling the story of a patient's agonising wait for a match. Launched in May 2019, the film brings to life our messaging that 'Without you, there is no cure.' You can watch the film and find out more at anthohnolan.org/withoutyou

2019–2020 will be an inspiring year at Anthony Nolan, as we are driven by the ambitious aims of our new strategy. We'll also be preparing to say a fond farewell to our Scientific Director, Professor Alejandro Madrigal who, after more than 25 years at Anthony Nolan, will retire in April 2020. Under Professor Madrigal's stewardship, the Research Institute has grown from strength-to-strength and now enjoys a global reputation for innovation and impact. We look forward to building on his remarkable and lifesaving legacy.

We have also said a big thank you and goodbye to Fran Burke, who used her experience of receiving a stem cell transplant to help others as a Trustee of Anthony Nolan, until her retirement last year. Fran joined the Board in 2002 – her personal experience and

commitment made her an anchor on the Board, and we are so grateful for her dedication over the years.

We are delighted to welcome two new trustees who joined the board in the year. Mark Ritson, who has received two stem cell transplants to treat severe aplastic anaemia, brings both his patient experience and knowledge from sitting on the board of the NHSE Clinical Reference Group for Bone Marrow Transplantation. Mark also has significant experience of business management and technology expertise.

Professor Antonio Pagliuca, a Consultant Haematologist and Professor of Stem Cell Transplantation at King's College London brings enormous experience and value to the board. During his time as Transplant Director over the past 25 years at King's, the hospital's transplant centre has become a Centre of Excellence, as he brings his vast haematology experience, and that of a Trustee for Leukaemia UK, to Anthony Nolan.

Over the last year, we have been inspired by the passion, professionalism and collaboration shown right across Anthony Nolan, and have seen time again that when we come together on projects, deepen relationships and unite our supporters, we can achieve more.

With now over 19,400 transplants facilitated since the charity began, there are thousands of patients and their families whose lives have been transformed by our work. And Shirley Nolan's vision of saving and improving the lives of everyone who needs a stem cell transplant still brings us all together, inspires action and remains as relevant today as ever before.



Henny Braund
Chief Executive



Ian Krieger
Chair

THE YEAR IN NUMBERS

OUR PATIENTS

1,425

patients were given a second chance of life. In 2017-18, we gave 1,393 patients a second chance of life.

12

Anthony Nolan Clinical Nurse Specialist positions have now been funded since the programme began, with two new additions in the last year. We've also funded four brand new Clinical Psychologists posts, across three transplant centres.

742

new patients have been cared for by our nurses, who have supported patients in clinics and wards over 1,600 times.

13,582

downloads and requests of our patient information booklets.

246

patient grants were provided in the year, totalling £53,492.

OUR STEM CELL DONORS

732,549

are now on the Anthony Nolan stem cell register at the end of 2018-19.

74,115

people have been recruited to join the stem cell register online and at events – 39% were young men aged 16-30, who are most likely to be chosen to donate. In 2017-18, 49,261 people were recruited to join the stem cell register.

5,343

young people were recruited from Hero Project talks in schools.

18,004

people were recruited by our 55 student Marrow groups, who have over 950 volunteers.

OUR OPERATIONS

2,355

searches for UK patients were carried out by our Search and Selection team. In 2017-18, we carried out 2,218 searches for patients in the UK.

591

Anthony Nolan donors donated stem cells to patients in the UK and abroad.

33

countries received our exported donors stem cells.

21

research studies have been running at the Anthony Nolan Research Institute.

OUR SUPPORTERS

was raised and donated by our dedicated supporters and partners.

1,324

runners, cyclists, swimmers and hikers took on a challenge in support of our lifesaving work, raising awareness and over £1.5m.

160k

followers now across Facebook, Twitter and Instagram.

166m

people reached by our online press and media articles, carrying key messages about who we are and what we do.

1.2m

visits to our website from supporters and patients.

WHAT WE DO

TRUSTEES' REPORT

Anthony Nolan saves the lives of people with blood cancer and blood disorders. We do this by connecting people in desperate need of a stem cell transplant with incredible strangers ready to donate their stem cells.

We are unique in bringing a growing register of potential donors together with both cutting-edge research and specialised patient services. Working together, we give three people a second chance of life every day.

Our Vision

To save and improve the lives of everyone who needs a stem cell transplant.

This is our defining vision and, if you're familiar with Anthony Nolan, you'll see it hasn't changed. That's because we're still driven by the same cause which inspired Shirley Nolan to found the organisation 45 years ago.

To ensure that we realise our vision, we introduced a three-year organisational strategy, *Saving Lives: Achieving More*, in October 2015. The strategy set out three core aims:

To improve outcomes and quality of life for our patients.

To lead and influence the global transplant community in improving outcomes.

To deliver excellence, efficiency and transparency in our work.

Having reached the end of our three-year strategy, 2019 offers a key opportunity to reflect and improve upon the successes of *Saving Lives: Achieving More*. These learnings will inform and streamline our work in the future so that we can maximise the benefit for patients.

Our Values

Every day at Anthony Nolan, we live and breathe our values to ensure that we can deliver the best for everyone, from transplant patients to corporate partners, supporters and staff. There are five values which guide our work. These commit us to always be:

- Accountable
- Passionate
- Patient-focused
- Innovative
- Improving every day

Our Objectives

We will help provide relief, treatment or cures to people with blood cancers and any similar immunological conditions.

We will facilitate potentially lifesaving stem cell transplants and provide patients, family members and carers with clinical and emotional support.

We will conduct research into the causes, treatment and cure of blood cancer.

We will drive forward research to improve stem cell transplants and publish our findings for public benefit.

These founding principles guide us in finding a donor for every patient who needs a stem cell transplant in the future. This is undoubtedly an ambitious goal. But with someone diagnosed with blood cancer every 14 minutes, it needs to be.

In the pages that follow, our Strategic Report and the inspiring stories featured show our commitment to achieving the best possible outcomes for patients to enable them to live a long and happy life post-transplant.

RUPERT AND BILLY'S ANTHONY NOLAN STORY

Connecting patients with incredible donors willing to donate their stem cells is at the core of our lifesaving work. Without them, there is no cure for people like Rupert.

Rupert was diagnosed with a blood disorder in 2016 when he was just seven years old. He needed a stem cell transplant to survive, so the search began for a matching stranger to give him a second chance of life. Thankfully, a donor was found, and Rupert was given back his future.

'Treatment was horrendous,' Rupert's mum, Holly, said. 'When Rupert was first diagnosed, you'd never have known he was so poorly. But he was just wiped out post-transplant, and so unhappy. He had no hair, his skin was yellow. I look back at photos and can't believe that was my child.'

FROM STRENGTH TO STRENGTH

After 88 days in hospital post-transplant, Rupert was allowed home. He was given his life back, all thanks to his donor. Rupert has gone from strength to strength ever since.

'Rupert was in bed for so long post-transplant that he had to use a wheelchair until his legs were strong enough. Now, he's playing football! And tennis, and going camping with the Scouts. He's doing everything a normal 10-year-old boy should do.'

MEETING BILLY

'Last year, two years post-transplant, we met Rupert's donor, Billy. It was so emotional. He did such an incredible thing. Thank you just isn't enough.'

Billy, 27, joined the register at a recruitment event at his workplace after chatting to a colleague in the queue. Little did he know that years later, he'd be saving Rupert's life... and marrying Kate, the woman he took a shine to in the queue!

'Since meeting Billy, we've been to the Anthony Nolan Supporter Awards and Daisy Ball together, sharing Rupert and Billy's story and shouting from the rooftops, "Join the register! You could be the one!"

'I'm so proud of Rupert. He's grabbing every opportunity and is full of so much love. On Mother's Day this year he gave me a handmade card that said "I will love you forever". But I will love him more than he will ever know.'

WHAT WE'VE ACHIEVED IN 2018–2019

STRATEGIC REPORT

In the last year of our 2015–2018 Organisational Strategy, Saving Lives: Achieving More, we have continued to focus on achieving our core aims as well as looking to the next chapter of our lifesaving work.

The following pages feature highlights of what we have achieved to deliver on these aims and tell stories of the people who we are committed to support, and those who are committed to support us.

PROGRESS AGAINST 2018-2019 OBJECTIVES

Last year, we identified priorities that are fundamental to realising our aims and aligned our operational plans and budgets to these priorities to ensure our efforts and investment can have the maximum impact. In the past year, 2018-19, we have worked towards six priority areas:

Patient focus: to support patients at every stage of their transplant journey and ensure our work is informed by their needs.

We have expanded our clinical nurse specialist programme, as well as added brand new clinical psychologist roles to focus on the psychological needs of transplant patients. These services seek to pilot new approaches and evaluate their impact on patient survival and quality of life.

Our Patient Services team have continued to expand their support, launching the new *My Transplant Tracker* app to help patients manage the long-term implications of transplant including health, fitness and coordinate appointments. We also created an enhanced grants programme to offer larger amounts to patients for higher levels of need.

Work has also continued on our post-transplant care pathway project. Consultations with patients, families and healthcare professionals have helped to comprehensively set out the services patients need after a stem cell transplant. Key messages and recommendations were positively received by the Expert Steering Group, and the report launched in May 2019.

Enriching the register: to target recruitment activity to groups that are currently under-represented on the register and ensure our recruitment approach reflects the latest research findings to help patients find the best possible match.

As our research shows that younger donors provide the best possible outcome for patients, we have continued to work in schools, universities and using targeted online advertising to help grow the stem cell register.

We also know that patients from black, Asian and minority ethnic (BAME) backgrounds can struggle to find a matching donor due to a lack of diversity on the stem cell register, and it's a key priority to change this. We know that there are limited options for targeting this group online, and have struggled to reach our target for BAME recruitment, so work has begun on partnering offline with organisations, schools and colleges in diverse areas, as well as exploring alternative solutions.

Raising awareness: to help recruit more donors and raise the funds we need to save more lives, we need to stay in the public eye to build understanding and support of our work. This includes key campaigning and communication messages that ensure patients' experiences and needs are heard by policy makers.

We have invested in developing research and insights to enable us to re-examine our brand from a fresh perspective. We have launched a new brand campaign in May 2019 focusing on the importance of a universal, emotive message to engage our supporter audience and increase our overall brand awareness.

We have continued to promote our key messages about who we are and what we do in our press coverage. We have also developed our storytelling ability with the help of a new Stories Manager, video strategy, and patron – award winning actress, Olivia Colman.

Our work with parliamentarians has also continued to help raise awareness of the stem cell register and how they can help recruit more potential lifesavers. This will help ensure that patients receive the best possible treatment, care and support.

Raising income: to provide consistent and expanding income streams to enable us to deliver on our aims for patients, including planning new income-generating initiatives. Our target in 2018-19 was to raise £11m from voluntary income.

With the help of our supporters and partners, we raised £9.7m in the financial year through a diverse range of activities. This was in the context of a challenging fundraising landscape: the effect of new data protection regulation; and numerous good causes similarly appealing for funds both from the public and potential corporate partners. We also made the decision in 2017 to cease our door-to-door fundraising, in part due to our perception that such activities might lead to reputational risk given the fundraising climate at the time. The subsequent impact of GDPR from May 2018 onwards has made it difficult to maintain our communications with these supporters, leading to higher than anticipated attrition rates, as well as difficulty in increasing the ask from existing supporters in 2018-19.

This year, we have made incremental improvements in many of our income streams and further reduced costs to improve our net income. We continue to have incredibly dedicated supporters who go above and beyond to raise money for our lifesaving cause.

During the year we brought together our community and events teams to deliver a more integrated experience for supporters. We also launched a brand new community fundraising activity, 'Walking Together' in Blood Cancer Awareness Month, which provides opportunities for our supporters to meet up, get outside and exercise, and enjoy fundraising for us together.

Our digital journey: to define our digital vision and better understand where we should invest in technology to strengthen our capacity, infrastructure and capability. This will enable us to connect with our supporters and achieve maximum impact for patients.

We have continued making progress to deliver our data improvement plan, which establishes standards and processes that govern the collection, storage, analysis and use of our data. A strong data community exists across the organisation enabling sharing of statistical data for insights and research, as well as personal data for legitimate purposes.

Our IT improvement programme 'Advance IT' has continued to move staff onto new systems that enable people to work in a mobile, supported and collaborative way. We've also worked on building the capability and capacity that aims to support all of our applications, and decrease dependency on legacy systems. This will equip us to respond better to our supporters' needs.

Our new Digital Engagement strategy sets out our mission to make our work in this area personal and purposeful. We embarked on several initiatives to help us to better understand everyone who engages with us. We can then improve our ability to meet the expectations of an increasingly digital audience. By growing our digital skills and expertise, together we can ensure that everyone can interact with Anthony Nolan in a meaningful way.

Laying the foundations for our new strategy: to define our aims for the next three years to take us into the 2020s, informed by our understanding of where and how we can maximise our lifesaving impact.

We have developed an ambitious new strategy to help prepare us for the future. This involved cross-organisational working groups to establish our priorities and direction of travel which was presented to all staff at our annual Summer Briefing.

Ideas, issues and concerns were taken on board from all levels of the organisation, helping to define our five key aims. Outline plans and budgets have been developed and agreed with the Board for the next three years, which are laid down against the new strategy and our priorities for the first year. You can read more about these on page 35.

AIM ONE

WE WILL WORK TO IMPROVE OUTCOMES AND QUALITY OF LIFE FOR OUR PATIENTS

Anthony Nolan's work is centred around finding the best possible matches for patients to give them the best possible chance of survival, a good quality of life, and a high standard of ongoing support.

Collaborating with transplant centres and clinicians is vital to achieving this aim in order to understand and deliver on their needs. This depends on recruiting and providing the best possible donors, growing our cord bank to help patients – particularly those from black, Asian and minority ethnic backgrounds who struggle to find a matching donor – and investing in translational research to help target our recruitment and inform clinicians' decisions.

We are all too aware that a transplant is just the beginning of a long road to recovery. We not only work with patients to understand what high-quality support looks like to them, but also provide ongoing care through Anthony Nolan's services to help ensure patients have the best possible quality of life after transplant.

Here are some of the things Anthony Nolan has been busy working on in 2018-19 to achieve our aim of improving outcomes for patients.

MATCHING PATIENTS AND DONORS

- In 2018-19, Anthony Nolan has given 1,425 patients a second chance of life – 1,340 through a matched unrelated donor and 85 through cord transplants, 10 of which came from the Anthony Nolan Cord Blood Bank. Finding matching donors for patients requires complex and time-critical work carried out by our team of expert staff, who have performed 2,355 searches for UK patients.
- We have been working to implement the Global Registry Identifier for Donors (GRID). GRID is an initiative of the World Marrow Donor Association (WMDA) and will mean that each donor worldwide will have a unique donor ID, removing the current risk of duplicate IDs. The process to implement GRID involves significant and ongoing IT development, as well as testing and communicating how it will work internationally.
- The Cord Support Programme, jointly developed with NHS Blood & Transplant (NHSBT), has continued to develop, focusing on education and training to share best practice and improve transplant centres' experience in requesting cord blood units (CBUs). Over the year, 65 UK patients benefited from the enhanced CBU search services. We now have five UK transplant centres subscribed to the Cord Support Programme, and have delivered 46 hours of free, on-site training sessions tailored to individual transplant centre needs.
- We know from our research that high quality typing, particularly of young male donors, makes it easier for transplant centres to find the best possible donors for patients. With this in mind, our Register Enrichment Programme continues to grow, with over 2,300 young men added to the Phenotype Project: a pool of 8,499 'super donors' who have high-resolution tissue typing, and further medical information on their record.
- A Donor Research Coordinator role has been introduced to understand and improve the donor experience, focusing initially on two key projects around donors' experience of donating via bone marrow, and looking at the specific experience of younger donors. We have already extended Healthcare at Home phlebotomy services to all donors to make providing verification typing blood samples easier.

MAKING THE BEST POSSIBLE MATCHES

- Our Patient/Donor project, led by Dr Neema Mayor, Head of Immunogenetics Research, and Professor Steven Marsh, Director of Bioinformatics, has continued to produce new findings. There are now 2,969 pairs in the project – 1,888 of which are typed using an ultra-high resolution sequencing technique that we call Third Generation Sequencing (TGS), which has revolutionised how we look at HLA genes. We fell just short of our target of getting 65% of all UK patient/donor pairs this year at 60%, but are working with transplant centres to increase the number of patient samples we receive in our plans for the coming year.
- The research has now reached a breakthrough in discovering why some matches are more successful than others. TGS has allowed us to confirm the importance of a sixth HLA gene and other genes which are crucial in determining the outcome of a match.
- Our joint proposal, between Anthony Nolan and the Centre for International Blood and Marrow Transplant Research (CIBMTR), to validate the findings from the TGS HLA typing study in a much larger cohort of patients was approved. This led to the manuscript's publication in the March 2019 Issue of the journal *Biology of Blood and Marrow Transplantation*, describing the improved patient outcomes when matching at TGS level.
- Matching to a higher level means we will be able to minimise the risk of complications such as graft versus host disease and, consequently, the risk of mortality – potentially saving more lives. This means looking beyond 10 out of 10 matching for patients to 12 out of 12 matches which can provide better outcomes – ultimately requiring donors to be typed to this higher level.
- Our research with CIBMTR has already featured in a number of medical journals. We will extend its impact by working with Transplant Directors, and Histocompatibility and Immunogenetics Laboratories, to promote the promising benefits of higher resolution sequencing using TGS.

RECRUITING AND RETAINING POTENTIAL LIFESAVERS

- The Anthony Nolan stem cell register grew to an incredible 732,549 potential stem cell donors by year end, with 74,115 people aged 16 to 30 recruited in the year – not only beating our overall target of 70,000, with a near equal spread across events and online recruitment, but reaching the highest recruitment number since 1986.
- We have also continued to work with expectant mums to grow the size of our cord bank. 1,410 clinical cord units were collected this year, bringing the total clinical banked inventory to 8,548 – in reach of our target to have a total of 10,000 cords banked by 2020. The stem cells in cord blood are less mature and can adapt to suit a wider range of tissue types, so can be a lifeline for people with no match on the donor register.
- Guided by research showing that the age of the donor can affect patient outcomes, with younger donors leading to better survival rates, we have continued to focus our recruitment on people aged 16-30, as well as to ensure more young people know about stem cell donation. Our Hero Project talks in schools for 16-18 year olds have recruited 5,343 donors this year, while our passionate student Marrow groups celebrated recruiting 18,004 donors in their 20th anniversary year. You can read more about this on page 34.
- Our vital partners continue to drive recruitment and reach more people: the Scottish Fire and Rescue Service (SFRS) expanded into new areas across Scotland including Dumfries, Aberdeen and Orkney; and the Adrian Sudbury Schools Education Trust (ASSET) celebrated the 100th person going on to donate stem cells – thanks to their Register & A Be Lifesaver (R&Be) education programme. Myles Holder signed up after hearing an R&Be talk in his school, and donated in July 2018.
- In one of our busiest years, 877 events took place in every corner of the country, many of them driven by community support for specific patient appeals. The

#MarrowForMarley patient appeal, for a young boy in Wales who needs to find a matching donor, was one of our biggest drivers of online registrations this year, with over 10,000 people applying to join the register – a number that's still growing.

- Everyone at Anthony Nolan was incredibly saddened to hear that six-year-old Kaiya Patel had died after receiving a stem cell transplant. Her family's #CureKaiya appeal for more donors to join the register saw an overwhelming response, and in November 2018 they collected Kaiya's Anthony Nolan Supporter Award for John Petchey Young Hero while she was in hospital, recognising the bravery she showed in sharing her powerful story.
- Although we didn't meet our overall target of recruiting 20% of potential donors from a BAME background, we recruited 14% holding a variety of targeted events during the year which we will continue to do in 2019-20.
- Targeted online recruitment of donors has seen over 12,000 people apply to join the stem cell register through a variety of different channels, including social media and podcast platforms. Our Halloween myth-busting campaign, 'Donating Isn't Scary', was hugely successful, driving more than 1,200 new donors to apply to join the register.
- 'Be A Lifesaver', our joint brand awareness and recruitment campaign targeting young men, told the story of Lamar Roberts – a professional basketballer from London who has joined the stem cell register. Young men are notoriously hard to engage with, but the film and accompanying adverts helped to recruit over 1,500 people to the register – two of those who joined have already gone on to donate their stem cells, potentially saving lives.
- With the appointment of a new Retention Manager, and developing a retention strategy, we have renewed our focus on donor retention to ensure Anthony Nolan donors are engaged, available and willing to donate when needed. Our donor availability has gone up slightly, from 65% in 2017-18 to 67% in the last year. Thanks to a variety of interventions including reviewing our communications, introducing new supporter journeys and working to optimise how we record data. Our ongoing target is 70% donor availability.
- To ensure potential donors are always contactable, we aim to encourage people on the register to regularly update their details. Although our regular campaign had to be put on hold largely due to our GDPR requirements, 34,018 people have updated their details in the last year – thanks in part to a targeted mailing we sent out on Valentine's Day.

SUPPORTING PATIENTS

- Our nursing programme has continued to grow, meeting our target for the year with two new Clinical Nurse Specialist (CNS) posts in the year. This brings our total to 12 funded positions who have supported patients in clinics and on wards more than 1,600 times this year. There are now also four brand new Clinical Psychologists posts across three transplant centres, solely focused on transplant patients' mental wellbeing.
- The Lead Nurse role introduced in 2017 has helped create more structure to the programme. This includes regular meetings with the CNS, encouraging structured reporting for regular feedback, and relationship building with transplant centres to build the business case for continuation beyond our funding.
- Our patient information has continued to evolve, with a year-long update and re-write of the website information being complete. We have updated our fatigue and mental health booklets and created our new leaflet 'Essential facts for Transplant Recovery'. We also published our 'Bereavement and Stem Cell Transplant' booklet to provide advice to relatives and friends who have lost someone after transplant. In total, our resources and guides have been downloaded or requested over 13,500 times.

- Our patient app *My Transplant Tracker* was launched in 2018 to help patients manage the long term progress of their transplant and monitor health, fitness and appointments, as well as providing an easy way to contact Anthony Nolan for support. It has now been downloaded over 960 times, with excellent feedback which patients are able to give live, via the app.
- The Patient Grants Programme has provided 246 grants to help patients with costs relating to their transplants such as travel to appointments. The programme was expanded in 2018 to create enhanced grants offering larger amounts for higher levels of need. In total, we provided £53,492 in grants to patients – an increase of 29% from 2017-18.
- There was good news for patients in Scotland when the Scottish Medicines Consortium approved the use of Prevymis (letermovir), a new treatment to prevent CMV reactivation post-transplant. We represented patients throughout the process to ensure their views were understood by decision-makers.

RINESH'S ANTHONY NOLAN STORY

It's simple – we couldn't save lives without the incredible people on our register, ready and waiting to save a life. But for many people, like Rinesh, going on to donate their stem cells is a life-changing experience.

'I joined the Anthony Nolan register 10 years ago. I was at our local temple where there was a recruitment event, and didn't think much of it. I was young with no responsibilities.'

GETTING THE CALL

'When I was then told I was a potential match, I was in total shock. On the one hand, I thought I was on the cusp of doing something amazing. But I was quite scared because I don't like needles!

'I felt quite proud to be a match with someone and felt a sense of responsibility that was immeasurable. I had to demonstrate a lot of courage to donate, but every nurse I met was supportive and funny. Anthony Nolan was always reassuring.

'The procedure was painless. I lost my appetite for a day or two, but I'm already back in the gym and playing football. I can't thank everyone involved enough. I was treated like a superstar 24/7. It felt a bit surreal as they were doing the hard work – I just had to turn up!'

A HUMBLING EXPERIENCE

'A lot of my family and friends were surprised when they found out I didn't know the patient. They assumed it was for a family member. This is the crux of the gift – it was purely selfless for a complete stranger. It was the most humbling act.

'I think about the recipient every single day. It's strange to think that a part of me is with them. I've given my recipient a chance at life – they've given me an experience that has changed the way I look at life forever. I appreciate things so much more. It really is an indescribable feeling.

'It's sad when I see statistics about the need for more people from minority ethnic backgrounds on the register. To be lucky enough to have been a match for someone of my ethnic background is a miracle.'

Our register is growing and diversifying day by day, year by year. But there is still more to do. Together, we're working towards a future where everyone will have their match – their lifesaver like Rinesh.

AIM TWO

WE WILL COLLABORATE WITH, LEAD AND INFLUENCE THE TRANSPLANT COMMUNITY IN IMPROVING OUTCOMES

Anthony Nolan is committed to supporting partnerships and joint working across the transplant field, so together we can achieve more.

Our work to deliver on this aim involves engaging with a huge variety of stakeholders, from other charities here in the UK, to international registers around the world, and from individual researchers, to biotechnology and pharmaceutical companies.

We know that together, by pooling knowledge and resources, we can achieve far better outcomes for patients than we could alone.

What follows are some of the ways we have been collaborating with, leading and influencing the transplant community in 2018/19.

COLLABORATING WITH PARTNERS

- IMPACT, the UK's stem cell transplant clinical trials network is now recruiting patients to two much-needed studies, with another two trials approved. The Expert Hub at the University of Birmingham is now fully resourced, including Research Nurses recruited at ten of the participating Transplant Centres. We are proud to be working in partnership with Leuka, NHSBT and the University of Birmingham on this important initiative, with our Chief Executive Henny Braund chairing the network.
- We established a Clinical Advisory Board, chaired by Dr Rob Danby, Consultant in Haematology, focusing on the translation of ex-vivo expanded stem cells for clinical use. This is incredibly valuable in strengthening our relationship with the clinical community and to improve understanding of the clinical application of cell products from cord blood.
- We have been working with Great Ormond Street, Hammersmith and Oxford hospitals on a Department of Health funded project to demonstrate the benefits of TGS typing in line with findings from our Patient/Donor Project. The Project is in its last stages with the final samples being typed before analysis.
- Our close work with the Catalan Banc de Sang I Teixits (Cord Blood Bank) in Barcelona, led by our Scientific Director, Professor Alejandro Madrigal, has continued. Earlier this year we undertook an official visit to the Bank and agreed upon future reciprocal exchanges of personnel for training in complementary areas. During the past year, we have continued our existing projects, examining ways to improve the outcome of cord blood transplantation. We have also investigated the impact of other cord blood products that could be used for the treatment of graft versus host disease and other inflammatory conditions, and are in the process of writing three papers for publication. This work will help to improve the outcome of transplantation in a large number of patients.
- We have been working with Department of Health and Social Care, NHS and other organisations from the Stem Cell Oversight Committee, taking forward recommendations from the Committee's 2014 report on stem cell transplantation in the UK. Work has included growing the cord bank and increasing the number of phenotype donors. Collaborating with these partners has been invaluable for understanding the stem cell transplantation landscape and identifying risks ahead. The current cycle of Department of Health and Social Care funding ended this year but we

are urging them to refresh the remit of the Committee, in order to access further funding, and to enable the continuation of this essential collaborative work.

- Research is showing that novel cellular therapies – such as CAR-T cells – can be used to successfully treat a wide range of conditions, including blood cancer and blood disorders. We continued to work with researchers to understand how we can best support their work, including through the provision of stem cells for use in research and development. To govern this work, we have established a specific donor policy for novel cellular therapies and an Independent Review Board (IRB), chaired by Dr Laura Machin, a Senior Lecturer in Medical Ethics at Lancaster University, to assess potential opportunities in this area.

LEADING THE TRANSPLANT COMMUNITY

- The sixth annual Graft Selection Strategy Workshop was hosted by us in June 2018, with over 80 delegates attending to share learning and approaches to donor and cord selection. The sessions included cell therapy, non-HLA genes, and the achievements and strategic direction of the Anthony Nolan and NHS aligned registry. The event continues to strengthen relationships across the aligned registry, increasing the understanding of work practices across registries and transplant centres.
- The Clinical Retreat, hosted in Manchester this year, featured discussion of the latest treatments such as CAR-T cell therapy and best practice in patient care. It remains the only opportunity for senior stem cell transplant clinicians in the UK to come together each year and have the space to debate and discuss issues collaboratively, and we're always delighted to hear each year from participants that it is such a valuable event.
- We have continued to play a leading role in the World Marrow Donor Association (WMDA). Henny Braund, our chief executive, is a member of the WMDA Board, which sets the organisation's strategic direction, and chairs the WMDA Search, Match and Connect Committee, which is delivering a major programme of IT change that aims to ensure all patients globally have equitable and efficient access to the best possible donor. This includes developing the Global Registration Identifier for Donors (GRID), a common Data Dictionary, security and privacy controls, as well as the global database and communication systems. We were instrumental in securing a multi-year grant from the EU to fund this vital programme.
- Our continued influence in the global community is demonstrated by the active part we play in all aspects of the WMDA's work and events. This includes representation on the WMDA Scientific Committee of the 2018 International Donor Registry Conference in Munich, at which Dr Neema Mayor – Head of Immunogenetics Research – led a debate on Full Gene Sequencing.
- Professor Steven Marsh, our Bioinformatics Director, has been elected to two positions at the Center for International Blood and Marrow Transplant Research (CIBMTR) – Co-Chair of CIBMTR's Immunobiology Working Committee and also as a Member at Large (Non-North America) on the CIBMTR Advisory Committee. Professor Marsh's election is testament to his, and our, standing in the international community, and could pave the way for more research collaborations with the US.
- Our first clinical nurse specialist (CNS) Education Day is scheduled for July 2019 where there will be over 20 delegates attending, all senior transplant nurses, from 14 different transplant centres. Topics include graft versus host disease biomarkers; management of sexual dysfunction; update on CAR-T cells; supporting Teenage and Young Adults with Cancer patients; and the importance of clinical supervision.

INFLUENCING KEY STAKEHOLDERS

- Throughout Blood Cancer Awareness Month, we ran the Communities vs Blood Cancer awareness campaign which aimed to raise awareness of stem cell donation among political stakeholders. The MP drop-in session in Westminster was our most

successful ever, with the team speaking to 83 MPs, including the Secretary of State for Health and Social Care and his Shadow counterpart. Our Policy and Public Affairs (PPA) team also held a campaign drop-in at the Scottish Parliament, attended by 53 MSPs, which included the First Minister.

- In 2018, our research showed that 62% of MPs recognised Anthony Nolan as having influence over cancer policy in Westminster, up from 46% in 2015. This is vital to helping raise awareness of the stem cell register, and how MPs can help recruit more potential lifesavers in their constituency, as well as ensuring that patients receive the best possible treatment, care and support.
- One of our key achievements over the past year was securing the Government's commitment to giving secondary school pupils in England the opportunity to learn the facts about stem cell donation and how it can give someone a second chance of life. Moving forwards, we hope to continue growing our influence not just in Westminster, but also in Holyrood.
- The Policy and Public Affairs team has continued to make progress with the development of the minimum standard for post-transplant care. The project's Expert Steering Group, chaired by Dr Fiona Dignan, developed a draft pathway which went through a consultation period inviting feedback from patients, their families and health care professionals. The resulting report, *A Pathway for Post-Transplant Care*, was published in May 2019.
- Over 80,000 people signed our petition to support Shirley Kordie, a patient who needed a transplant from her brother – a nurse living in Ghana. The Home Office refused him a visa because he didn't earn enough money. So, working with the ACLT (African Caribbean Leukaemia Trust), we and our petitioners helped get the decision overturned.

ANTHONY NOLAN CLINICAL NURSE SPECIALISTS UPDATE

Since 2014, we have been funding, recruiting and supporting clinical nurse specialists (CNS) based in UK transplant centres, to help raise the standard of post-transplant care.

WHY DO WE NEED POST-TRANSPLANT CNS?

At Anthony Nolan, we have researched the provision of post-transplant care across the UK. Our policy reports – *Road Map to Recovery* (2013), *Destination Cure* (2015) and *Who Cares?* (2017) – highlighted inconsistencies and gaps within this care.

The clearest outcome was that not all post-transplant patients have a dedicated, named CNS. This gap in service provision can have a detrimental impact on a patient's quality of life and their ability to recover successfully.

Our most recent report, *A Pathway for Post-Transplant Care* (May 2019), set out the minimum standard of care that was developed in consultation with patients and experts in the clinical community. We know that part of the support we can help provide is our team of CNSs.

WHAT DOES AN ANTHONY NOLAN POST-TRANSPLANT CNS DO?

As experienced healthcare professionals, each Anthony Nolan CNS has expert knowledge of the unique needs of transplant patients and they are in the ideal position to be able to provide comprehensive care.

In the last year, our nurses have seen 742 new patients and have supported patients in clinics and wards over 1,600 times. They address the medical needs of patients, as well as their emotional and psychological wellbeing.

Each nurse broadly undertakes a similar role, though we believe that for our clinical programme to be truly effective, each should be tailored to the specific needs of patients, as well as areas of care that existing staff feel are lacking resource.

For example, our CNS have been developing late effects clinics to ensure patients get the ongoing care they need. Lorna Welsh, our CNS at Queen Elizabeth University Hospital Glasgow, set up a telephone late effects clinic for patients who live a long distance from the hospital. Jess Fuidge, our paediatric CNS at Bristol Royal Hospital for Children, also runs an outreach follow up clinic in Belfast and Cambridge, which is an excellent example of shared care.

WHAT DOES THE FUTURE HOLD FOR ANTHONY NOLAN CNS?

To help more patients and their families have equal access to services and support, at whatever stage in their recovery and for as long as they need it, we are funding more Anthony Nolan CNS, as well as introducing new clinical psychologist roles, and collaborating with the transplant, nursing and clinical community to raise the standard of care.

AIM THREE

WE WILL DELIVER EXCELLENCE, EFFICIENCY AND TRANSPARENCY IN OUR WORK

Anthony Nolan is committed to living our values so we are ready to deliver the best for everyone – our supporters, staff, partners, fundraisers, volunteers and, most importantly, the patients we are committed to help.

We aim to uphold standards that we can be proud of and which enable us to expand our reach and save more lives. This includes increasing awareness to leverage support of our charity, as well as raising the money that will ensure we have the right funding in the right place to deliver our aims.

Over the last year, we have developed insight to help inform this progress, and have focused on attracting, retaining and developing the outstanding individuals that work together at Anthony Nolan to save more lives.

The following pages show some of the ways we have delivered excellence, efficiency and transparency in 2018/19.

INCREASING AWARENESS

- In May 2018, we launched our integrated brand awareness and register development campaign, 'Be A Lifesaver'. Our Creative Studio team won the Award for 'best collaboration with an external agency' at the In-House Design Awards. The campaign was delivered across a range of channels including TV advertising on Sky, digital advertising, social media, email and PR. Cutting through the noise of multiple communication channels to reach our audiences and to encourage young people can be a challenge but this campaign video has to date been seen by over 5 million people.
- Our aim is to achieve 60% of prompted awareness, and to increase our brand comprehension so people not only know our name, but understand our lifesaving work. We have invested in developing research and insights to enable us to re-examine our brand from a new perspective, understand the importance of a universal, emotive message to engage our supporter audiences and develop the new big brand idea launched in May 2019. Our current awareness levels are on average 55%.
- Our new Stories Manager has helped centralise how we gather and share stories from our amazing supporters, patients and donors, as well as work with them on brand new opportunities for sharing their experiences – including films, in communications and at events. We had our first 'Stories Live' event with Sonny, a stem cell donor, coming in to the office to give an engaging account of his donating experience.
- The 2018 Anthony Nolan Supporter Awards (ANSAs) were held for the first time in the grand setting of the Tower of London, allowing us to host over 200 guests and celebrate our supporters' many achievements. It was an inspirational evening, with dedicated supporter, Holly Cross, sharing her son Rupert and his donor Billy's incredible story live on the night – see page 14 to read more.
- Our digital channels have continued to grow, with over 160,000 followers across Facebook, Instagram and Twitter. This means when a patient needs our help, we have the reach to help get their story out there to thousands of people, including Harri's patient appeal which reached over 750,000 people and gained more than 111,000 post clicks – making it one of our most-engaged-with posts of all time.

- As part of our strategic drive to become more personal and purposeful, we have appointed a digital and user experience agency to conduct User Research which will enable us to develop a better understanding of who our audiences are and gain insight into their needs and motivations. One of the key outputs will be restructuring the information on our website, allowing us to meet our supporters' needs and expectations more effectively.
- With our new approach to storytelling and our video strategy, we have developed more informational and story-led videos to increase our output, including the 'My Anthony Nolan Story' series which offers an insight into the lives of people who have a special connection with Anthony Nolan. This has helped promote our celebrity engagement as well, with our patron Olivia Colman's film launched early this year, and actress Kellie Shirley's and presenter Joe Crowley's films are in production.
- Anthony Nolan's work featured in 2,900 press articles across the year – with 72% featuring at least one key message about what the charity does or the support we need – just beating our target of 70%. Online, we had a reach of over 166m sharing stories of patient appeals, campaigns and PR successes – including patients featuring on Davina McCall's show 'This Time Next Year' twice!

RAISING LIFESAVING FUNDS

- Thanks to our fantastic supporters and partners, we raised a total of £9.7m in 2018-19.
- We launched our first new campaign in Community Fundraising, 'Walking Together', in Blood Cancer Awareness Month, September 2018. The campaign encouraged supporters to take on their own sponsored walk. We saw a fantastic response, with over 250 enquiries. 55 events took place across the country against our stretch target of 100, and the campaign still raised over £34,000 – a very strong start for a new project – which took just a few months to pull together. 2019's Walking Together campaign will be launched further in advance to give supporters the time they need to plan their walks.
- Our partnership with The Jack Petchey Foundation to educate, inspire and recruit young people into our register through the Hero Project in London and Essex reached its fifth year. We were also delighted to receive further support from The Foundation with a grant to provide top quality post-transplant care for patients through a Clinical Nurse Specialist at Barts Hospital in London, one of the busiest transplant centres in the country.
- The Tracey Sollis Leukaemia Trust and The Steel Charitable Trust generously supported the Anthony Nolan Research Institute with grants towards the purchase of equipment to further our pioneering research. We have also been kindly supported by The Robertson Trust and The Westfield Health Charitable Trust who awarded us grants to fund our Marrow programme, providing vital resources to help recruit more potential lifesavers.
- Our committed Corporate Partners have continued to enable our lifesaving work, including our longest standing partner, RSM, who agreed to sponsor our volunteer courier programme for a fourth year with an even greater donation. They attended a very special event to celebrate 10 years of our couriers, including Stephen Berger who is both a Consultant at RSM and a volunteer courier himself. RSM also won Organisational Fundraiser of the Year at our Anthony Nolan Supporter Awards 2018 in recognition of their vital contribution.
- We also launched a new strategic fundraising partnership with London estate agents Marsh & Parsons, based around our common interest in matching people. They're aiming to raise £25,000 through employee fundraising over the course of the year. We're hugely grateful to all our funding partners who make such valuable contributions to our lifesaving work.

- We held our first Business Breakfast which saw businessman Sir Martin Sorrell speak alongside Mike Felton, who received a transplant a few years ago, to a room full of potential supporters from the business world. The event has enabled us to start conversations with potential partners, who are also keen to explore working together and developing lifesaving, mutually-beneficial partnerships.
- Events with supporters coming together are highlights in our year, and the 2018 Daisy Ball was another brilliant success. This unforgettable night saw Isabelle Providence, a patient and Daisy Ball committee member, share her moving story, and raised £308,000. We're incredibly grateful to the continued support of our sponsors, including Furniture Village.
- Our supporters continued to amaze and inspire us with their fundraising activities including the London Marathon, during which they raised over £590,000 and the Great North Run, with our biggest team ever of 295 runners raising over £180,000. We also had large numbers joining #TeamAN at the Edinburgh Marathon Festival and the Belfast Marathon, including Belfast Marrow, cheered on by our growing supporter base in Scotland and Northern Ireland.
- In May 2018, the General Data Protection Regulation (GDPR) came into effect, and we worked to ensure we had collected compliant email consents from all types of supporters. Our opt-in rate is just over 21%, which means a reduction in the number of supporters we can speak to, but compares favourably with other organisations, and we have found in some campaigns that on average, supporters have a higher response rate.
- Informing people about opting-in to marketing and fundraising, as well as communications, to those on the stem cell register, remains a key priority for us: approximately 50% of people joining the register don't opt in to hear about other aspects of our work, making it more difficult to engage with them longer term. We will work hard next year to ensure our communications are relevant and appropriately targeted so we engage the greatest number of people, and retain and deserve their loyalty, to help us achieve our aims.
- We launched 'Facebook Donate' in April 2018, allowing supporters to set up their own fundraisers in aid of Anthony Nolan on the social media platform. In the first year, 395 people set up fundraisers, over 5,000 people donated and together raised over £79,000. We also started using the Facebook Donate button to raise funds and awareness for patient appeals, which has seen an promising response.

LOOKING AFTER OUR PEOPLE

- The result of the Best Companies survey this year highlighted many positive – and gave us our highest-ever placing in the 100 Best Not for Profit Organisations to Work for 2018 at number 51. But there is lots to work on to achieve our ambition of becoming a two-star ('outstanding') employer by 2020. Our HR team has been working with the divisions to develop follow-up action plans.
- In November 2018, we started a review of the culture of Anthony Nolan to explore what is or isn't working well, using all the knowledge we've gathered from the staff survey and fairness survey as well as feedback taken from discussions with individual staff and teams across all divisions. We all agreed that, just as our organisational strategy is ambitious and seeks to differentiate us from other organisations, so too should our culture. The priorities include leadership, staff development, internal communications, diversity, respect and inclusion. We seek to make sure that, regardless of the division our staff work in or the location, Anthony Nolan deserves its status as one of the best places to work. We expect work to continue on this through 2019 and 2020.
- In May, our HR team launched 'Elements' – a new online HR self-service system offering staff easy access to information such as their payslips, as well as managing holidays and sickness leave more efficiently online rather than using paper forms.

- HR are working on our three-year employer brand project to better communicate what it's like to work at Anthony Nolan for potential and existing staff. This will start with the candidate and new starter experience, alongside ensuring we attract the best quality candidates through our recruitment and selection procedures.
- A dedicated learning and development role was added to the HR team in early 2019 to help us to attract, train and develop outstanding individuals. Key focus will be on developing the training offer across the organisation, standardised recruitment processes, apprenticeships and managers programmes.
- We held our second annual 'Wellbeing Week' with a huge range of activities for staff to engage with and promote wellbeing – from drum lessons to cholesterol checks, and a trip to the local city farm. Alongside running regular training for 'managing mental health at work' and access to monthly clinical supervision sessions, we have continued to promote the importance of staff wellbeing.
- Our new Volunteer Development Manager is developing our Volunteer Strategy to ensure that we attract, retain, train, support and recognise the contribution and value that volunteers bring to Anthony Nolan.

IMPROVING EFFICIENCY AND EFFECTIVENESS

- Our Supporter Relationship Management team have introduced new software across the organisation, including Alteryx for advanced data analytics work, and Tableau to help visualise our data. This has enabled more teams to make use of vital data from higher quality and more timely reports throughout the year.
- Our IT team continued to deliver the Advance IT infrastructure programme to move staff onto new systems that enable the workforce to work in a mobile, supported and collaborative way. This is especially important for remote workers, and to relieve us of our dependency on legacy systems that continue to experience challenges. The team is migrating everyone over to Windows 10 and Office 365, as well carrying our phishing campaigns to support our cyber security and replacing analogue fax with an electronic system for Operations and Patient Services.
- The Applications Development team is focusing on ensuring we have the capability and capacity to support all of our applications and develop better ways of working for everyone including updating our stem cell register database to a cloud platform to deliver additional benefits, and working to enhance the Search platform to improve accuracy.
- Our Facilities team continue to keep the gears of Anthony Nolan moving efficiently, including refurbishing the Anthony Nolan Cell Therapy Centre in Nottingham. A space study, looking at how we use space across our London office, was conducted as the start of our journey moving towards more agile working practices.
- At Anthony Nolan, we recognise our responsibility to safeguard and protect the welfare of all children and vulnerable adults who are involved in, or affected by, our work. Having safeguards in place not only protects and promotes the welfare of children and vulnerable adults, but also enhances the confidence of trustees, staff, volunteers, corporate partners, parents/carers and the general public. During this period we rolled out our revised safeguarding policy and procedures, our e-learning package for safeguarding children and adults and a series of face to face training events to staff and volunteers.
- Planning for leaving the European Union continues to be a major priority as the date of the UK's departure remains uncertain. We have been predominantly working on two main challenges, the regulatory environment and potential disruption to travel as well as providing reassurance to patients and supporters. While it remains an evolving situation, we are confident we have done everything we can to minimise any potential disruption. We have communicated with our customers and invited them to come to us should they have any concerns.

- To better engage with our supporters, we've begun a programme of work called 'Transform', which will launch in the next financial year. 'Transform' will enable us to provide ways for everyone to join our lifesaving community which are mutually beneficial. We need to deliver an outstanding experience to our community by communicating with them in a meaningful, appropriate and timely way to enable us to have more impact for patients. We will be looking at systems, culture and ways of working that can further deepen our relationships.

KIMBERLY'S ANTHONY NOLAN STORY

In September 2018, Kimberley Pearson took part in the inaugural year of Walking Together – Anthony Nolan's new fundraising event for Blood Cancer Awareness Month – for a very personal reason.

Kimberley's dad was diagnosed with leukaemia in 2007, and his prognosis was devastating. Given just six weeks to live, the search began to find him a matching stem cell donor.

Amazingly, a matching donor was found and his transplant was successful. He lived for another happy and healthy 10 years with his family and friends, before his leukaemia returned. Sadly, this time it was more aggressive and he died in 2017.

'At my dad's funeral, instead of having flowers, we collected donations for Anthony Nolan. A few months later, I received an email about Walking Together, saying "Would you like to do something?" and I love fundraising, so got on board to organise an event in Bristol.

'There was so much flexibility. You weren't expected to move mountains. Even if you just walked around the park, there was a real sense of bringing people together for something important.'

WALKING TOGETHER

Kimberley was one of the very first people to take part in Walking Together. She called her walk the 'Big Bristol Stroll', and advertised it as a six-mile walk around some of Bristol's famous sites.

'There is something really magical and special about people coming together for a cause. Unbelievably, nearly 50 people came out for the Big Bristol Stroll. It was a great way to encourage a community to come together.'

LASTING LEGACY

'We handed out balloons and leaflets, and explained how people could support the charity. We even had someone with us who had been on the Anthony Nolan register and had in fact been a donor, so that was amazing!'

Kimberley's event was a great success, raising £1,627.60. Together, they raised awareness and funds – giving her late dad an incredible legacy.

'After losing my dad, I have found that fundraising has been a way of channelling my grief into something positive. Everyone will have their own personal reason for supporting Anthony Nolan – mine is because they gave me and my family 10 extra years with my dad.'

OUR VOLUNTEERS

Volunteers and supporters are the lifeblood of Anthony Nolan. Selfless with their time and generous with their contributions, they are influential in shaping the face of the organisation, and we couldn't do what we do without them.

From travelling couriers and passionate school speakers, to our lifesaving donors and all the people who lead community events, 1,634 volunteers supported us during the 2018/19 year. We are particularly grateful for the incredible contribution of our partners including Scottish Fire and Rescue Service, Adrian Sudbury School's Education Trust, Rik Basra Leukaemia Campaign and African Caribbean Leukaemia Trust, who have worked tirelessly to recruit thousands of potential lifesavers across The UK.

We are very fortunate to have such a committed group of people helping us achieve our strategic aims to improve outcomes and quality of life for our patients, and to deliver excellence, efficiency and transparency in our work.

Volunteer Managers are in place across the organisation to identify training and support needs, and ensure our volunteers are recognised as a key part of our workforce. Our volunteers also have a dedicated Safeguarding Lead to apply our Safeguarding Policy and identify and address potential risk areas.

VOLUNTEERING ROLES AT ANTHONY NOLAN:

Peer Support Volunteer

Online Community Champion

Patient and Families Panel

Young Ambassador

Office Volunteer

Laboratory Assistant

Laboratory Administrator

Marrow Student Volunteer

Donor Recruitment Event Volunteer

Schools Volunteer Presenter

Volunteer Courier

Donor Visitor

Phenotype Project Volunteer

Fundraising Volunteer, including challenge events and community fundraisers

MARROW ANTHONY NOLAN STORY

Marrow, Anthony Nolan's incredible network of volunteer student groups, has been celebrating its 20th anniversary this past year. Having grown to over 50 groups in universities across the country, Marrow has now recruited over 130,000 potential donors to the stem cell register. Their work is truly remarkable.

WHERE IT ALL BEGAN...

Marrow was founded in 1998 at Nottingham University by Dr James Kustow, a third-year medical student at the time who had heard that his childhood friend, Karen, had been diagnosed with chronic myeloid leukaemia.

'Although we were no longer in close touch, it hit me hard as she was such a lovely person. I felt that I couldn't just sit there and do nothing. After doing a bit of research, I got in touch with Anthony Nolan and organised what I initially intended to be a one-off donor recruitment clinic with some fellow medical students.'

After a successful event, Dr Kustow saw the potential of the model and decided to set up a committee to build on and develop the vision for Marrow. Over the subsequent years, trained groups of students began to spring up across the country, shaping into the inspirational force we see today.

'Now, in my role as an Anthony Nolan trustee, I continue to always maintain one eye on Marrow – this unique, young, intelligent workforce that is such a central, valuable and respected body within the charity.'

Dr Kustow has also been recognised for his achievements by Nottingham University, who presented him an Alumnae Laureate 'Special Excellence' Award in 2017.

MARROW'S 20TH YEAR

20 years on, over 1,300 people recruited by Marrow have gone on to donate their stem cells to someone in need of a lifesaving transplant. And that couldn't have happened without the dedicated Marrow volunteers, like Nottingham Marrow's President, Jesse.

'I joined Marrow after being inspired by the previous president, Kiran, who committed so much time and effort to Marrow. It's not just a student-led volunteering project – it's a way of life!

'My favourite part is training up new volunteers. It's so rewarding to see them go from super nervous to confident lifesavers. But the TV appearances on BBC and ITV are obviously amazing too!'

OUR FUTURE

TOGETHER, WE CAN SAVE LIVES

We are very proud of the progress we have made during our 2015-2018 strategy, Saving Lives: Achieving More, and are now excited to launch new 2019-2022 strategy, Together, We Can Save Lives.

Our new strategy is all about preparing ourselves to be fit for the future; making sure we have the culture, ways of working, resources and infrastructure to ensure every patient can benefit from research findings, innovative treatments and the best care that can be offered.

The strategy has been developed over the last year in collaboration with trustees, colleagues, patients and partners. The insight generated from this engagement was instrumental in setting our future strategic direction, ensuring we are able to build on success, learn from experience and lay the strongest foundations for future impact.

The strategy sets out what we want to achieve in the three years, 2019-2022, and beyond. It is underpinned by an operational plan and budget that sets out what we will do and achieve in pursuit of our strategic aims to deliver on our vision.

There is inevitable uncertainty ahead. We want to be ready to react to change, as well as play a leading role in shaping it. This means bolstering our influence and remaining agile so we can protect and promote the interests of our patients.

Our strategy is structured around five key aims. These are outlined on the following pages, with key areas of focus for the next three-year period.

STRATEGIC AIMS 2019-2022

AIM 1 – TOGETHER, WE CAN PROVIDE OUTSTANDING SERVICES FOR PATIENTS AND THE CLINICAL COMMUNITY

We will listen closely to the needs of patients and the clinical community, and then work as One Anthony Nolan in order to fund and deliver outstanding services. As well as our existing work, we are also going to explore and support the development of innovative treatments, and campaign and advocate so that all patients have access to them.

We will strive to:

- Use our expertise and infrastructure to support the development of innovative treatments.
- Pilot, demonstrate and advocate for new patient services and reduce the critical 'time to transplant' for patients.

AIM 2 – TOGETHER, WE CAN DRIVE LIFESAVING RESEARCH AND TURN IT INTO ACTION FOR PATIENTS

We're proud of the impact our pioneering research has had on patients' lives. But we know there's still so much more to learn. We will be leaders in discovering the many factors that influence the success of a stem cell transplant, and be catalysts for change by ensuring patients see the benefits of research sooner.

We will strive to:

- Increase the number of clinical trials and develop a research platform with the clinical community to work towards our shared goals.
- Ensure more patients see the benefits of trials and research translated into faster treatment and care.

AIM 3 – TOGETHER, WE CAN HARNESS THE COLLECTIVE POWER OF OUR SUPPORTERS TO CHAMPION AND ENABLE OUR LIFESAVING WORK

Together, we can achieve far more than we could alone. We want more people to hear about Anthony Nolan and to be able to say 'yes' to everyone who wants to take action and get involved. From incredible mums donating their cord to Marrow student volunteers passionately promoting our work, tireless fundraisers and generous funders, to selfless stem cell donors – there's a place for everyone to proudly be part of our lifesaving community.

We will strive to:

- Build the profile of the organisation to increase support for the charity.
- Collaborate with our lifesaving partners to develop our supporter base, growing and enriching the stem cell register, and diversifying our income so we can achieve our ambitious goals.

AIM 4 – TOGETHER, WE CAN BE A STRONGER VOICE FOR PATIENTS TO ENSURE THEY RECEIVE THE BEST POSSIBLE CARE

Over the last 45 years of our lifesaving work, we have built the authority and credibility to influence and effect change. Through this strategy, we want to effect a step-change in our influencing to ensure we can have a wide-ranging and sustainable impact. As well as lobbying and campaigning to make patients' voices heard, we want to use the insight we generate through our work to change policy and practice so it benefits all patients, both now and in the future.

We will strive to:

- Increase awareness and understanding of our work and impact to help make demonstrable policy and practice changes
- Use our expertise and collective voice to promote patients' interests

AIM 5 – TOGETHER, WE CAN

This is an ambitious strategy, and it needs to be. Our work is vital and urgent, and we owe it to patients – now and in the future – to aim high. Just as important as what we want to achieve, is how we will achieve it. We all need to work smarter, with the right tools to do our jobs, informed by our behaviours and living our values of being accountable, passionate, patient-focused, innovative and improving every day.

We will strive to:

- Improve efficiency and effectiveness using technology, data and insight.
- Work more collaboratively in pursuit of shared aims with patients, clinicians, partners and across the organisation

HOW WE OPERATE 2018-2019 (TRUSTEES' REPORT CONTINUED)

ORGANISATIONAL STRUCTURE

Anthony Nolan is a registered charity and a company limited by guarantee incorporated in England and Wales. Every member undertakes to contribute an amount not exceeding £1 to the assets of the charity in the event of the charity being wound up during the period of their membership, or within one year thereafter. The members, who are the Trustees, are also the Directors of the charity. The charity's governing document is in the form of a Memorandum and Articles of Association revised and updated on 6 April 2017.

The overall strategic direction of the charity is determined by the Trustees, who meet formally at least five times each year. The Trustees are responsible for planning and policymaking for Anthony Nolan and, accordingly, all key decisions are referred to and taken by the Board of Trustees. The Chair of the Board is Ian Krieger.

There is one formal sub-committee of the Board – the Audit and Finance Committee, chaired by Carol MacKinnon. The Committee enables the Trustees to consider issues on finance, risk, matters relating to the external audit as well as internal controls in more detail where needed. The Committee meets approximately two weeks in advance of each Board meeting. Carol MacKinnon was appointed Vice-Chair of the Board in January 2019.

The day-to-day management of Anthony Nolan is entrusted to the Chief Executive and the Strategic Leadership Team, who have delegated authority from the Board to administer the affairs of the charity. There is a short, closed session at the start of each Board meeting. The Chief Executive and Strategic Leadership Team are then invited to join the main part of the Trustees' meetings and provide them with updates on the work of Anthony Nolan.

The Chief Executive and Strategic Leadership Team meet regularly throughout the year to discuss and consider strategic and operational activities as well as review monthly financial and management information.

RECRUITMENT, APPOINTMENT, ELECTION, INDUCTION AND TRAINING OF TRUSTEES

RECRUITMENT AND APPOINTMENT

Appointment to the Board of Trustees is by invitation after the needs of the charity and a range of suitable candidates are considered by the Trustees. The number of Trustees is subject to a maximum of 20 and must be greater than three.

ELECTION

Under the Memorandum and Articles of Association, the Trustees retire from the Board by rotation every four years with the option of re-election for up to a maximum of three terms. A rotation plan is in place to ensure the phased retirement of existing Trustees to ensure business continuity as new Trustees are appointed.

The Trustees aim to ensure that the composition of the Board has the right balance of skills and expertise and is made up of individuals with suitable backgrounds and experience to contribute positively to the governance of Anthony Nolan. Since the members of Anthony Nolan are the Trustees and Directors, election and re-election is determined by the current Board in all cases.

INDUCTION AND TRAINING

The work of Anthony Nolan involves continuously advancing scientific and medical processes of stem cell transplants. To keep Trustees aware of the charity's operations on both a national and international level, sessions are arranged to update them on facets of

Anthony Nolan's work, either during Trustees' meetings or at separate meetings. Two advisory groups, one on Medical and Scientific Affairs and another on Technology, include external experts and practitioners in those areas to provide further guidance and advice. At least one member of the Board sits on each group and reports back to the Trustees. Presentations by outside advisers relating to specific governance issues are organised as appropriate. The induction of a new Trustee is tailored to the individual concerned and includes: a guided tour of the charity's operations; an introduction to key staff; and an outline of the duties and responsibilities of being a Trustee and Director. All newly appointed Trustees are provided with an Induction Pack of key documents and information relating to Anthony Nolan. The January Board meeting each year includes refresher induction sessions for all Trustees.

DECLARATION OF INTERESTS

At each board meeting, there is a standing agenda item for each board member to declare their interests. Each financial year, all Trustees complete a Declaration of Interests form and new Trustees complete a Fit & Proper Person Declaration, as recommended by HMRC. Declarations of Interests are also completed by members of the Strategic Leadership Team, Assistant Directors and Company Secretary.

REMUNERATION OF KEY MANAGEMENT PERSONNEL

The Board of Directors, who are the charity's Trustees, together with the Strategic Leadership Team, comprise the key management personnel of the charity, as defined by FRS102. All Trustees give their time freely and none receives remuneration. Trustees are entitled to claim reasonable expenses under the charity's Expenses Policy. Trustees' expenses during the year are disclosed in note 11. There were no related party transactions during the year. The pay of the Strategic Leadership Team, and any pay increases, are approved by the Chair of the Board of Trustees. Remuneration is reassessed as required when job vacancies are advertised based on a sense check across relevant sectors.

EMPLOYEES

Anthony Nolan provides an inclusive working environment for employees and one which supports professional and personal development.

Anthony Nolan is committed to fostering a culture of diversity, respect and inclusion as well as equality of opportunity for all employees. Employment practices and policies are in place to ensure that no employee, or potential employee, receives less favourable treatment because of age, disability, gender reassignment, race, religion or belief, sex, sexual orientation, marriage and civil partnership, co-parenting, pregnancy and maternity/paternity.

CHARITY GOVERNANCE CODE

Anthony Nolan supports the seven principles of good governance laid out in the Charity Governance Code. As a charity registered in Scotland, as well as England and Wales, Anthony Nolan also supports the five core best practice principles laid down in the Scottish Governance Code 2018. A review of the Governance Codes was undertaken by our Audit and Finance Committee and discussed by the Board in January 2019. Anthony Nolan aspires to follow best practice guidelines at all times. The review showed that the Charity generally performs well under the Code. We have identified the following areas for further development:

Diversity – A Diversity and Inclusion Advisory Group was set up in March 2019 by the Board, Chaired by Trustee Dr Chonnetia Jones, to examine the Board's diversity, respect and inclusion practices and to consider the development of a Diversity Policy in line with the Governance Code's recommendations.

Self-appraisal and feedback – All new Trustees are invited to informal two-way feedback meetings with the Chair one year after appointment. A new self-appraisal process has

been put in place for all Trustees from May 2019 and a new Vice-Chair, Carol MacKinnon, was appointed in January 2019 to be an additional channel of communications between individual Trustees, the Chair and the Board.

Board appointments process – A new Governance, Nominations and Remunerations Committee to be set up in 2019 will review the Board's existing selection processes for the appointment of new Trustees. Its remit includes ensuring that the current skills analysis is fit for purpose and that the appointments process is properly reviewed and documented to meet the standards of openness and transparency recommended by the Code.

Number of Trustees – Currently, the Anthony Nolan Board has 15 Trustees. As part of the Board's rotation plans the number of Trustees, as well as the expertise identified as necessary for decision-making, enables a degree of succession planning and stability so that new Trustees can benefit from the experience of the longer-serving members.

Terms of office – the Code advises that no Trustee should serve for more than nine years and any serving for more than that period should be subject to rigorous review to take account of the need for refreshing the Board balanced with the need to retain experience of the business. Twelve of our Trustees have served for five years or less, while three Trustees have served for more than nine years: the Chair was unanimously elected by the Board to serve for a new term of office of four years from 1st January 2018; while two other Trustees' terms of office were reviewed in April 2017 and their appointments were subject to unanimous re-election by the Board to serve new terms of office of four years.

SAFEGUARDING

A Safeguarding Policy is in place and published on the charity's website. The policy and compulsory training for staff, as well as training for volunteers identified as requiring inductions for working with the charity, are subject to regular review by the Designated Safeguarding Lead Director together with the Leads for Staff and Volunteers, Patients and Donors. Arrangements are in place for staff and volunteers to report concerns to independent, external third parties to ensure at all times that matters can be raised without fear or favour. All trustees have completed our compulsory safeguarding training.

WHISTLEBLOWING

It is important that any fraud, misconduct or wrongdoing by staff, permanent or temporary, or volunteers, including Trustees, acting on behalf of Anthony Nolan is reported and properly dealt with. A Whistleblowing Policy is in place to ensure that people can safely raise concerns and feel confident they will be listened to, their concerns will be properly investigated and acted upon appropriately.

EMPLOYEE INFORMATION

The Strategic Leadership Team regularly provides information to employees through a variety of communications including the publication of a quarterly magazine distributed to staff, all-staff briefings held at least once a year, and weekly emails from the Chief Executive to all staff. Information, news, policies and resources are shared via the widely-used staff intranet, Matchbook. Regular consultations are held with staff through Anthony Nolan's Staff Forum which includes a representative from every division. Employee views are also sought through web-based surveys, focus groups and team meetings.

ANTHONY NOLAN TRADING

Anthony Nolan Trading Limited (ANTL) is a wholly owned subsidiary of Anthony Nolan. This subsidiary plays a crucial role in fundraising on behalf of the charity and the principal activity of ANTL is to carry on the trading operations of the group with a view to raising funds. This is achieved through advertising, selling merchandise, fundraising events and utilising intellectual and similar rights held by the parent charity.

PROFESSIONAL INDEMNITY INSURANCE

The charity has taken out an insurance policy that provides professional indemnity insurance cover for the Trustees. The cost of this insurance for the period was £3,377 compared with £3,347 in the previous year.

RISK AND CORPORATE GOVERNANCE MATTERS

Anthony Nolan operates a robust risk management process. Risks are identified and managed at an organisational, directorate and project level. Risk registers are used to detail the risks identified, their potential impact, and likelihood of occurrence. They also include the controls and plans in place to mitigate against the risks. The charity's major risks are reviewed in detail at least annually by the Audit and Finance Committee and the risk register is approved by the Trustees.

Our ability to continue to save patients' lives, and improve their quality and length of life, depends on having sufficient funding in place. Therefore, continuity of income remains a key risk for the charity, particularly given it is in part dependent on NHS policy. A range of actions have been, and continue to be, implemented including continuing to work closely with UK transplant centres and international registries, working on ways to diversify our income portfolio, continuous improvement in our approach to financial management, and investment in our brand to help raise our profile.

In September 2018, a proportion of the Charity's reserves were invested into a share portfolio under the management of Smith and Williamson Investment Management LLP. An Investment Policy, agreed by the Board, is in place with the objective of producing the best financial return with an acceptable level of risk. The policy includes restrictions on the purchase of stocks with revenues from tobacco production. The portfolio and its management is kept under regular review by the Audit and Finance Committee on behalf of the Board.

In the process of carrying out our lifesaving work, the health and safety of donors, patients, staff and volunteers is of paramount importance. We have a range of controls in place to mitigate the risk of any potential harm to individuals including health and safety training; inductions and guidance for our staff and volunteers; medical check assessments in place before the donation process; verification procedures in place to ensure correct identification of patients and donors prior to transplant; and risk assessments carried out for all events.

Our Quality Team plays a key role in ensuring that the charity operates in accordance with all medical and scientific regulatory requirements. This includes ensuring compliance with the Human Tissue Authority, which licences our registry and our cord blood bank in Nottingham to carry out our lifesaving work; and our accreditation by the World Marrow Donor Association. Our Histocompatibility Laboratory is also accredited by the United Kingdom Accreditation Service and the European Federation for Immunogenetics. Our Cord Blood Bank holds National Ethical Approval to act as a research tissue bank and has FACT-NetCord accreditation.

The loss or misuse of personal data that the charity holds for all its patients, donors, financial supporters, staff and volunteers is also considered a major risk. To mitigate against this risk, we have clear data protection and confidentiality policies, and induction and training in place. There are also technical solutions in place to ensure any personal and sensitive medical data is encrypted and transmitted securely. These policies and procedures are communicated to staff and volunteers and monitored by a standing Data Security and Protection Working Group. Internal notification of data loss/misuse reporting processes are in place to identify, investigate and mitigate against any potential issues with regard to the use of personal data.

A Privacy Office has been established to ensure that data privacy impact and legitimate interest assessments, are completed where necessary. Policies and procedures comply with the requirements of the General Data Protection Regulation (GDPR), and our Data

Protection Officer reports directly to the Board. A charity wide data mapping exercise was completed in 2017 and reviewed in May 2019, data processing agreements are in place where required, and a robust procedure implemented to respond to Subject Rights Requests: during the 2018/19 year end period, seven Subject Access Requests and 16 Rights to Erasure Requests were received. All were resolved within the required one month timeframe. IT security policies are in place to ensure that our systems are secure and regularly reviewed, with appropriate disaster recovery measures in place.

After the UK's decision in 2016 to withdraw from the EU, we undertook a risk assessment to examine the potential impact on Anthony Nolan and our work. In particular we examined: disruption to the import and export of stem cells, including the potential divergence over time of regulatory regimes for stem cells and clinical trials; disruption to business-critical supply chains; changes to the employment and residency rights of EU staff-members; and access to EU research funding and collaboration, including the ability of UK researchers to secure EU funding and to join / lead pan-European research partnerships. We continue to put in place mitigating plans, and assess potential impacts, to ensure our life-saving work and research is uninterrupted through the Brexit negotiations and beyond.

Contracts management procedures are in place to make sure that all supplier contracts operate in the best interests of the charity. New suppliers are subject to an appraisal process including standard requirements for declaring interests and agreements to comply with our Modern Anti-Slavery Policy. A Delegation of Financial Authorities Policy and Schedule is in place to determine signing authorities for contracts, as agreed by the Board. All contracts over £250,000 are reported quarterly to the Audit and Finance Committee, and any with a value of £1m or higher are signed by the Chair and reported to the Board. A conflict of interests declaration is a standing item on each Board agenda.

As required by the Charity Commission, a serious incidents reporting policy is in place and during the year no serious incidents were reported.

BUSINESS PLANNING

Each year, Anthony Nolan conducts a cross-organisational planning exercise which serves to translate our strategic ambition into actions and targets. In parallel, our annual budgeting process ensures we are deploying resources in line with strategic objectives and financial parameters. Since 2015, three-year strategic business plans have been agreed with the Board as we plan for the development of new treatments, new ways of working and new opportunities to save and improve more lives. Operational planning is informed by a review of our operating environment, which supports us to identify emerging opportunities and assess risks to mitigate. Each year, the Strategic Leadership Team and Trustees identify our fundamental priorities for the year ahead, which provide a framework for the prioritisation of effort and resource deployment. Operational plans and budgets are scrutinised through the lenses of value for money and strategic alignment to ensure our activities and expenditure deliver maximum impact.

PUBLIC BENEFIT

The Trustees, in exercising their powers and duties, have complied with their duty in section 4 of the Charities Act 2011 and have had due regard to the public benefit guidance published by the Charity Commission. In preparing the report and accounts the Trustees have complied with the requirements set out in the guidance to report on the significant activities and achievements of the charity in 2018-2019. They have reported in a way that both sets out the aims and strategies of the charity and demonstrates how the aims and activities of the charity were carried out for the public benefit.

TRUSTEES' AND DIRECTORS' RESPONSIBILITIES IN THE PREPARATION OF FINANCIAL STATEMENTS

The Trustees (who are also the Directors of Anthony Nolan for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial

statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and the group as at the balance sheet date, and of the incoming resources and application of resources, including the income and expenditure for the charitable group, for that period.

In preparing those financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities' SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether the applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable group, and enable them to ensure that the financial statements comply with the requirements of The Companies Act 2006, The Charities Act 2011, The Charities and Trustee Investment (Scotland) Act 2005 and The Charities Accounts (Scotland) Regulations 2006 as amended.

They are also responsible for safeguarding the assets of the charitable company and the group, and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The Trustees are responsible for the maintenance and integrity of the corporate and financial information on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

THE FINANCIAL REVIEW

2018/19 has seen another year of stable financial performance which has enabled us to maintain reserves alongside a significant increase in the level of investment in charitable activities. This has enabled us to facilitate even more transplants in the year than in prior years, add 74,115 potential lifesavers to our stem cell register and collect a further 1,410 clinical cords. In addition, we continue to invest more in our patient services and continue valuable research work, all of which further supports our aims of improving patient outcomes and saving more lives.

A small surplus of £0.1m was recorded in the year across all funds; however free reserves (general funds net of designated funds and the net book value of fixed assets) grew from £8.7m to £10.2m.

INCOME AND EXPENDITURE

Income including net gain on investments totalled £53.8m, an increase in the year of £2.0m (4.0%). Donor provision fees continued to be the main source of income for the charity, raising £43.1m (2017/18: £40.6m). Donor provisions increased for export purposes but there was a slight reduction in the UK. Gross voluntary income reduced to £9.7m from £10.2m due to the combined effects of continued attrition within Individual Giving and the implementation of GDPR affecting how we could contact supporters. Net voluntary income fell to £6.0m from £6.5m. We raised a further £463,000 from fundraising activities through our trading subsidiary Anthony Nolan Trading Limited, making the total fundraising income £10.1m. In total, our trading subsidiary generated operating profits of £104,000, all of which was distributed to the charity in the year.

Total expenditure was £53.7m, an increase of £4.7m (9.6%) from the previous year. Expenditure to raise donations and legacies remains unchanged at £3.7m (2017/18: £3.7m), however expenditure on charitable activities increased to £49.7m (2017/18: £45.0m). Within charitable activities, £42.9m was spent on donor provision giving a chance of life to 1,425 patients. £2.7m was spent on research, with £2.5m funded from net voluntary income. We spent a further £4.0m on education and awareness events that support our donor recruitment, campaigning and fundraising activities.

Included in total expenditure are support costs of £9.9m (2017/18: £8.4m) equating to 18.4% of income and reflecting investment in our technology infrastructure.

RESERVES POLICY

Anthony Nolan's policy with regard to reserves is to make suitable investment in the ongoing development of the charity, while maintaining adequate funds to deal with current and medium-term needs and having the necessary provision to deal with unforeseen circumstances. The Trustees have determined that the optimal level for free reserves is between £8m and £12m, that in the medium term, free reserves should be managed to reach this level to deal with the following:

Requirements for a reasonable level of working capital, taking into account our growth.

Period of time required to downsize the charity operations if necessary, to respond to any downturn in income streams or reduced demand for donors.

Period of time to re-establish income streams.

Free reserves at year end amounted to £10.2m compared to £8.7m in the previous year. This reflects reduced restricted and designated funds and net book value of tangible fixed assets. The board has set a target reserves level of between £8m and £12m. There will be further investment in technology during 2019/20 and the trustees consider it prudent to hold higher levels of free reserves in the short-term. Trustees continue to work with the Strategic Leadership Team to review our reserves regularly. Designated funds decreased

to £0.8m from £1.4m as earmarked funds for raising awareness and enriching our register were utilised.

DESIGNATED FUNDS:

Funds to be spent in the next 12-18 months are designated for:

Digital and technology – £500,000 is now designated for specific technology projects. This is aligned with our technology strategy recognising the continuing need to invest more in digital and technology to improve systems and processes and ensure delivery of excellent customer service. This fund was re-designated having originally been put aside as a property fund. Following assessment of our current property needs and the likely extension of some of our property leases the need for a property fund is deemed to be more of a medium-term priority and funds will be designated in due course

Innovation fund – £300,000 has been designated to fund new income generating activities. The appropriate level of reserves of the charity will continue to be reviewed regularly.

AUDITOR

RSM UK Audit LLP has indicated its willingness to continue in office.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITOR

The Trustees who were in office on the date of approval of these financial statements have confirmed as far as they are aware, there is no relevant audit information of which the auditor is unaware. Each Trustee has confirmed that they have taken all the steps that they ought to have taken in order to make themselves aware of any relevant audit information, and to establish that it has been communicated to the auditor.

FUNDS HELD AS CUSTODIAN

Although the charity maintains restricted funds to deal with incoming resources that are earmarked for a particular purpose by donors, sponsors, and other funds, Anthony Nolan does not currently hold, and the Trustees do not intend that it will in the future hold, any funds as custodian for any third party.

The Trustees' Annual Report is approved by order of the Board of Trustees and the Strategic Report (included therein) is approved by the Board of Trustees in their capacity as the directors at a meeting on 9 July 2019 and signed on their behalf by:



Chair, Ian Krieger

Date: 9/7/19

INDEPENDENT AUDITORS' REPORT TO THE TRUSTEES AND MEMBERS OF ANTHONY NOLAN

OPINION

We have audited the financial statements of Anthony Nolan (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 March 2019 which comprise the Consolidated and Parent Charitable Company Statement of Financial Activities, the Consolidated and Parent Charitable Company Balance Sheets, the Consolidated and Parent Charitable Company Cash Flow Statements and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 March 2019; and of the group's and the parent charitable company's incoming resources and application of resources, including their income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

BASIS FOR OPINION

We have been appointed auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the group's or parent charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

OTHER INFORMATION

The other information comprises the information included in the Trustees' Annual Report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover

the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINIONS ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the directors' report and the strategic report, prepared for the purposes of company law and included within the trustees' annual report, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report and the strategic report, included within the trustees' annual report, has been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of the knowledge and understanding of the group and the parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the directors' report and the strategic report, included within the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the statement of trustees' responsibilities set out on page 41 the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group's and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will

always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at <http://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

USE OF OUR REPORT

This report is made exclusively to the members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006 (as amended). Our audit work has been undertaken so that we might state to the members and the charitable company's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, its members as a body, and its trustees as a body, for our audit work, for this report, or for the opinions we have formed.

RSM UK Audit LLP

Date: 12 July 2019

NICHOLAS SLADDEN

(Senior Statutory Auditor)

For and on behalf of RSM UK AUDIT LLP, Statutory Auditor

Chartered Accountants

25 Farringdon Street

London

EC4A 4AB

RSM UK AUDIT LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006

THANK YOU

Working together with our supporters means we can do more for the patients who need us. So to every one of you who braved a challenge, hosted an event, remembered us in a will or raised awareness of our work – thank you. Without you, there is no cure.

Particular thanks goes to the organisations and individuals listed here, who are providing outstanding financial support or partnering with us to recruit more lifesaving donors.

Adrian Sudbury Schools Education Trust
African Caribbean Leukaemia Trust
All the Friends Groups and Tea Bars of Anthony Nolan
Budapest Airport-anna.aero Runway Run
Cairn Energy
Covent Garden Tenants Association
Dig Deeper Adventure Race
FDM Group
Focus Leukaemia
Fraser Sharp
Friends and family of Alice Byron
Friends and family of Jo & Charlie Henderson
Friends and family of Mark Falliaze
Friends and family of Sophie Miller
haysmacintyre
HelpHollie
Holly Cross
Jack Petchey Foundation
Jacqui Loth
Mani Ponnusamy
Marsh & Parsons
Niblock Family
Paul and Gail Corrigan
Police Scotland
Pride of Paddington
Rik Basra Leukaemia Campaign
RSM
Sam Milliken Smith
Scottish Fire and Rescue Service
Simeon Barnett
Stephen Armstrong and Jacob's Journey
Team Aspen
Team Edwards
Team Sandies
The Robertson Trust
The Staff & Artists of the Royal Opera House
The Steel Charitable Trust
Tile Giant
Tracey Sollis Leukaemia Trust
Westfield Health Charitable Trust

Our work at Anthony Nolan often involves complex legal questions on contracts and projects, including when they involve areas outside of the law of England and Wales. While we have a strong in-house team, and occasionally paid lawyers, we receive excellent pro bono support from external law firms as part of their Corporate Social Responsibility

programmes. We are very grateful to the following firms and their staff who provided us with pro bono legal advice:

CMS

DLA Piper UK (including from their English, Scottish, Canadian and Italian offices)

Simmons & Simmon

ANTHONY NOLAN & SUBSIDIARY UNDERTAKING

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
(Including Consolidated Income and Expenditure Account)
for the year ended 31 March 2019

	Notes	Unrestricted Funds £'000	Restricted Funds £'000	TOTAL 2019 £'000	Unrestricted Funds £'000	Restricted Funds £'000	TOTAL 2018 £'000
INCOME FROM:							
Donations and legacies	2	9,359	320	9,679	9,799	410	10,209
Charitable activities							
Donor provision	5	43,084	-	43,084	40,615	24	40,639
Research	6	40	216	256	102	211	313
Other trading activities	3	531	-	531	446	-	446
Investments	4	147	-	147	99	-	99
Other	7	18	-	18	41	-	41
TOTAL INCOME		53,179	536	53,715	51,102	645	51,747
EXPENDITURE ON:							
Raising funds:							
Expenditure on raising donations and legacies	8	3,720	-	3,720	3,706	-	3,706
Expenditure on other trading activities	3, 8	331	-	331	298	-	298
Charitable activities:							
Donor provision	8	42,557	386	42,943	37,669	366	38,035
Education and awareness	8	3,999	-	3,999	2,919	-	2,919
Research	8	2,524	204	2,728	3,765	279	4,044
TOTAL EXPENDITURE		53,131	590	53,721	48,357	645	49,002
NET (EXPENDITURE)/INCOME BEFORE INVESTMENT GAINS		48	(54)	(6)	2,745	-	2,745
Net gains on investments	14	78	-	78	-	-	-
NET INCOME/(EXPENDITURE)		126	(54)	72	2,745	-	2,745
TRANSFERS BETWEEN FUNDS	24	66	(66)	-	206	(206)	-
NET MOVEMENTS IN FUNDS		192	(120)	72	2,951	(206)	2,745
RECONCILIATION OF FUNDS							
Total funds brought forward	24	13,653	689	14,342	10,702	895	11,597
TOTAL FUNDS CARRIED FORWARD	24	13,845	569	14,414	13,653	689	14,342

ANTHONY NOLAN & SUBSIDIARY UNDERTAKING
PARENT CHARITY ONLY STATEMENT OF FINANCIAL ACTIVITIES
(including Parent Charity Only Income & Expenditure Account)
for the year ended 31 March 2019


	Notes	Unrestricted Funds £'000	Restricted Funds £'000	TOTAL 2019 £'000	Unrestricted Funds £'000	Restricted Funds £'000	TOTAL 2018 £'000
INCOME FROM:							
Donations and legacies	2	9,359	320	9,679	9,799	410	10,209
Charitable activities							
Donor provision	5	43,084	-	43,084	40,615	24	40,639
Research	6	40	216	256	102	211	313
Investments	4	251	-	251	158	-	158
Other	7	114	-	114	130	-	130
TOTAL INCOME		52,848	536	53,384	50,804	645	51,449
EXPENDITURE ON:							
Raising funds							
Expenditure on raising donations and legacies	8	3,720	-	3,720	3,706	-	3,706
Charitable activities:							
Donor provision	8	42,557	386	42,943	37,669	366	38,035
Education and awareness	8	3,999	-	3,999	2,919	-	2,919
Research	8	2,524	204	2,728	3,765	279	4,044
TOTAL EXPENDITURE		52,800	590	53,390	48,059	645	48,704
NET (EXPENDITURE)/INCOME BEFORE INVESTMENT GAINS		48	(54)	(6)	2,745	-	2,745
Net gains on investments	14	78	-	78	-	-	-
NET INCOME/(EXPENDITURE)		126	(54)	72	2,745	-	2,745
TRANSFERS BETWEEN FUNDS	24	66	(66)	-	206	(206)	-
NET MOVEMENTS IN FUNDS		192	(120)	72	2,951	(206)	2,745
RECONCILIATION OF FUNDS							
Total funds brought forward	24	13,593	689	14,282	10,642	895	11,537
TOTAL FUNDS CARRIED FORWARD	24	13,785	569	14,354	13,593	689	14,282

CONSOLIDATED & CHARITY BALANCE SHEETS

as at 31 March 2019

	Notes	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
FIXED ASSETS					
Tangible assets	13	2,804	3,493	2,804	3,493
Investments	14	3,093	-	3,093	-
		<u>5,897</u>	<u>3,493</u>	<u>5,897</u>	<u>3,493</u>
CURRENT ASSETS					
Stocks	15	574	553	574	553
Debtors	16	10,325	9,006	10,748	9,192
Cash at bank and in hand	17	7,755	10,166	7,068	9,773
		<u>18,654</u>	<u>19,725</u>	<u>18,390</u>	<u>19,518</u>
LIABILITIES					
Creditors: Amounts falling due within one year	18	8,763	7,309	8,559	7,162
		<u>9,891</u>	<u>12,416</u>	<u>9,831</u>	<u>12,356</u>
NET CURRENT ASSETS					
		<u>9,891</u>	<u>12,416</u>	<u>9,831</u>	<u>12,356</u>
TOTAL ASSETS LESS CURRENT LIABILITIES					
		<u>15,788</u>	<u>15,909</u>	<u>15,728</u>	<u>15,849</u>
Creditors: Amounts falling due after one year	19	806	999	806	999
Provisions for liabilities	22	568	568	568	568
		<u>14,414</u>	<u>14,342</u>	<u>14,354</u>	<u>14,282</u>
NET ASSETS					
THE FUNDS OF THE GROUP & THE CHARITY					
Restricted income funds	24	569	689	569	689
Unrestricted income funds					
General Fund	24	13,045	12,219	12,985	12,159
Designated funds	24	800	1,434	800	1,434
		<u>14,414</u>	<u>14,342</u>	<u>14,354</u>	<u>14,282</u>
TOTAL GROUP & CHARITY FUNDS					
	24,25	<u>14,414</u>	<u>14,342</u>	<u>14,354</u>	<u>14,282</u>

The financial statements on pages 50 to 70 were approved by the trustees and authorised for issue on 9/7/19 and are signed on their behalf by

 Chairman
 Ian Krieger

ANTHONY NOLAN & SUBSIDIARY UNDERTAKING

CONSOLIDATED & CHARITY STATEMENTS OF CASH FLOW
for the year ended 31 March 2019

	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES				
Net income for the reporting period	72	2,745	72	2,745
Adjustments for:				
Depreciation	1,138	1,218	1,138	1,218
Tangible fixed assets written off	-	13	-	13
Gains on investments	(93)	-	(93)	-
Interest and rents from investments	(147)	(99)	(251)	(158)
(Increase)/decrease in stocks	(21)	77	(21)	77
Increase in debtors	(1,319)	(1,013)	(1,556)	(1,196)
Increase in creditors	1,261	691	1,204	695
Increase in provisions	-	200	-	200
Net cash provided by operating activities	891	3,832	493	3,594
CASH FLOWS FROM INVESTING ACTIVITIES:				
Interest and rents etc. from investments	147	99	251	158
Purchase of property, plant and equipment	(449)	(525)	(449)	(525)
Purchase of investments	(3,000)	-	(3,000)	-
Net cash used in investing activities:	(3,302)	(426)	(3,198)	(367)
(DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS	(2,411)	3,406	(2,705)	3,227
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF PERIOD	10,166	6,760	9,773	6,546
CASH AND CASH EQUIVALENTS AT THE END OF PERIOD	7,755	10,166	7,068	9,773

The changes in cash and cash equivalents due to exchange rate movements in the year were £1k decrease (2018: £43k decrease).

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

CHARITY INFORMATION

Anthony Nolan is a company limited by guarantee (registered number 02379280), which is a public benefit entity and registered as a charity in England and Wales (charity number 803716), and Scotland (SC038827), and domiciled in the UK. The address of the registered office is Royal Free Hospital, Pond Street, London NW3 2QG.

1 ACCOUNTING POLICIES

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

a) BASIS OF ACCOUNTING

The financial statements have been prepared in accordance with Accounting and reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102); the Companies Act 2006, The Charities Act 2011 and the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. The reporting currency is pound sterling.

Anthony Nolan meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

b) BASIS OF CONSOLIDATION

The consolidated accounts incorporate the result of Anthony Nolan and its wholly owned subsidiary undertaking, Anthony Nolan Trading Limited, on a line by line basis. The consolidated entity is referred to as 'the group'.

c) GOING CONCERN

The Trustees have reviewed the group's and the charity's forecasts and projections covering a period that exceeds twelve months from the date of signing these financial statements, and based on the level of existing cash and estimated levels of income and expenditure, the trustees are satisfied that the charity has adequate resources to continue in operation for the foreseeable future. Accordingly, the going concern basis has been used in preparing these financial statements. Trustees have also considered there are no material uncertainties in the operating environment.

d) INCOME

Income is recognised when the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Donations are accounted for when either receivable or there is sufficient evidence to suggest that it is probable and there is entitlement to the income. Donations are stated gross of any attributable tax recoverable. Sponsorship income from events is recognised when the event takes place.

Income from government and other grants are recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably. Donations and grants given for specific purposes are treated as restricted income.

Income from legacies is recognised when probate is granted and there is sufficient information to value them. Reversionary interest involving a life tenant is not recognised. Where a payment is received from an estate after the reporting date and before the accounts are authorised but it is clear that the payment had been agreed by the executors prior to the end of the reporting period, then it is treated as an adjusting event and accrued as income.

Income in respect of payments for transplants and other similar services derives from the amounts charged in respect of the search for matching tissue types and the arrangement of the transplants, and is accounted for when transplant or other procedure takes place. It is classed as income from charitable activities.

Rental income on assets leased under operating leases is recognised on a straight line basis over a lease term and is presented within the investment income.

e) EXPENDITURE AND ALLOCATION OF SUPPORT AND GOVERNANCE COSTS

All expenditure is accounted for on an accruals basis inclusive of any irrecoverable Value Added Tax. Expenditure on charitable activities includes grants payable to other institutions and individuals. Where costs cannot be directly attributed, they are allocated to categories on a basis consistent with the budgeted use of the resources concerned and in proportions based upon a suitable ratio applicable to the nature of the cost involved. The basis of allocation of support and governance costs is analysed in Note 10.

Redundancy and termination benefits are recognised in the period in which the charity commits to incur the costs. These costs are allocated on the same basis as other expenditure.

Grants to third parties are charged in the year when an award is approved by the relevant award panel and the commitment is communicated to the recipient, except in cases where the offer is conditional. Such grants are recognised as expenditure when conditions are fulfilled.

The cost of volunteers' time is not accounted for as this cannot be measured reliably.

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

ACCOUNTING POLICIES (continued)

f) FOREIGN CURRENCIES

Transactions denominated in foreign currencies are recorded using the rate of exchange ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the rate of exchange ruling at the balance sheet date. All exchange gains or losses are included in the statement of financial activities in the period to which they relate.

g) FINANCIAL INSTRUMENTS

Basic financial instruments

The group has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

h) RESEARCH AND DEVELOPMENT EXPENDITURE

Expenditure on research and development is written off to the Statement of Financial Activities in the period in which it is incurred.

i) TANGIBLE FIXED ASSETS

All tangible assets purchased costing more than £1,000 that have a useful economic life that exceeds one year are capitalised and classified as fixed assets, the exception being computer equipment, which is all capitalised, even if the cost is lower than £1,000. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value over its expected useful life, as follows:

Leasehold buildings	over the life of the lease
Leasehold improvements, fixtures & fittings	over 3 to 4 years
Office equipment (including computer equipment and software)	over 3 to 5 years
Laboratory equipment	over 3 to 5 years

j) IMPAIRMENT OF FIXED ASSETS

An assessment is made at each reporting date of whether there are indications that a fixed asset may be impaired. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairment losses.

k) FIXED ASSET INVESTMENTS

Investments, including bond and cash held as part of the investment portfolio investments are measured at fair value. The basis for measuring fair value is bid price. Realised and unrealised gains and losses in the year are included in the statement of financial activities.

l) STOCKS

Stocks are valued at the lower of cost and net realisable value. Stocks that have reached the expiry date are written off at the point of expiry.

m) LEASED ASSETS AND OBLIGATIONS

Rentals payable under operating leases are charged to the Statement of Financial Activities on a straight line basis over the lease term.

n) TAXATION

The company is a registered charity and as such its income and gains falling within Sections 471 to 489 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992 are exempt from Corporation tax to the extent that they are applied to its charitable activities.

Costs are recorded gross of VAT but the group is able to reclaim a proportion of VAT paid, because of its trading activities, using the partial exemption method.

The subsidiary company distributes any taxable profits to the charity each year under Gift Aid.

o) PENSION CONTRIBUTIONS

The group and the charity make contributions into defined contribution pension schemes on behalf of certain employees. The assets of the schemes are held separately from those of the group and the charity in independently administered funds. The amount charged to the Statement of Financial Activities in respect of pension costs is the total contributions payable for the year.

p) FUND ACCOUNTING

The general fund comprises the accumulated surpluses of unrestricted incoming resources over resources expended, which are available for use in furtherance of the general objectives of the charity.

Designated funds are part of unrestricted funds which Trustees have earmarked for a particular project or use, without restricting or committing the funds legally. The designation may be cancelled by the trustees if they later decide that the charity should not proceed or continue with the use or project for which the funds were designated.

Restricted funds are funds subject to specific conditions imposed by funders. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the period end are carried forward in the balance sheet. Where the specific conditions of the donation are met so the funds are no longer restricted in purpose or use, unspent amounts are transferred to the general fund.

Restricted income spend on fixed assets, such as laboratory equipment, is shown as a transfer to the unrestricted fund at the point of purchase, once the terms of the restriction have been met.

q) PROVISIONS

Provision is made by the group and the charity for liabilities and charges arising from legal or constructive obligations that exist at the balance sheet date. The amount is calculated on the basis of the estimated cost to settle the present obligation or transfer it to a third party at that date. Consideration is given to the timing of the cash flows and to future events and uncertainties which may affect the amount required to settle the obligations.

CRITICAL ACCOUNTING JUDGEMENT AND SOURCES OF ESTIMATION UNCERTAINTY

Estimates and judgements are continually evaluated and are based on historical evidence and other factors, including expectations of future events that are believed to be reasonable under circumstances.

Critical judgements in applying the charity's accounting policies

(i) Dilapidation costs

In estimating the dilapidation costs relating to the leases of premises a provision is calculated in accordance with the amount per square foot. This is applied from the start of the lease and increased with the addition of new premises or according to the surveyor's estimates.

ANTHONY NOLAN & SUBSIDIARY UNDERTAKING

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

2 DONATIONS AND LEGACIES INCOME	Unrestricted Funds £'000	Restricted Funds £'000	TOTAL 2019 £'000	TOTAL 2018 £'000
Group & Charity				
Donations	8,451	310	8,761	9,712
Legacies	908	10	918	497
	9,359	320	9,679	10,209

3 TRADING OPERATIONS & INVESTMENTS

The charity has one wholly owned subsidiary, Anthony Nolan Trading Limited ("ANTL"), a company registered in England & Wales (Company number 02511952, registered office: The Royal Free Hospital, Pond Street, London NW3 2QG). The charity acquired 99 ordinary shares of £1 each that were issued in ANTL at par upon incorporation. These shares are carried in the balance sheet at their original cost of £100.

The principal activity of ANTL is to carry on the trading operations of the group with a view to raising funds on behalf of the parent charity, which is achieved through the sale of merchandise, advertising, the organisation of fundraising events, and by exploiting intellectual property and other similar rights held by the parent charity. Annual financial statements for this subsidiary company are filed with the Registrar of Companies for England and Wales, and are publicly available.

At 31 March 2019, the value of ANTL's net assets was £61k (2018: £61k) matching the value of the shareholder's funds. Current assets were £802k (2018: £460k) and current liabilities £741k (2018: £399k).

In the year ANTL made a turnover of £531k (2018: £446k) and interest income of Nil (2018: £1k), and expended £427k (2018: £387k), including a share of central costs payable to Anthony Nolan (Note 29), thereby generating operating profit of £104k (2018: £60k). The sum equivalent to the taxable profits was distributed to Anthony Nolan.

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

	Unrestricted Funds £'000	Restricted Funds £'000	TOTAL 2019 £'000	TOTAL 2018 £'000
4 INVESTMENT INCOME				
Group				
Rent receivable under operating leases	81	-	81	82
Investment income	21	-	21	-
Bank interest receivable on short term cash deposits	45	-	45	13
Royalty income receivable	-	-	-	4
	147	-	147	99
Charity				
Rent receivable under operating leases	81	-	81	82
Investment income	21	-	21	-
Bank interest receivable on short term cash deposits	45	-	45	13
Royalty income receivable	-	-	-	3
Anthony Nolan Trading Ltd: Gift aid distribution	104	-	104	60
	251	-	251	158
5 DONOR PROVISION INCOME				
Group & Charity				
Fees receivable for the provision of donors	42,224	-	42,224	39,604
Support income in relation to donor processing	860	-	860	1,035
	43,084	-	43,084	40,639
6 RESEARCH INCOME				
Group & Charity				
Grant income receivable	40	216	256	313
7 OTHER INCOME				
Group				
Other income	18	-	18	41
	18	-	18	41
Charity				
Anthony Nolan Trading Ltd: recharge of costs	96	-	96	89
Other income	18	-	18	41
	114	-	114	130

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

8 ANALYSIS OF EXPENDITURE

Group	Activities undertaken directly		Grant funding of activities	Support costs (note 10)		Total Costs
	Staff costs	Other costs		Staff costs	Other costs	
	£'000	£'000		£'000	£'000	
2018/2019						
Expenditure on:						
Raising funds						
Expenditure on raising donations and legacies	1,242	1,403	-	407	668	3,720
Expenditure on other trading activities	-	331	-	-	-	331
Charitable activities:						
Donor Provision	7,736	28,251	75	2,896	3,985	42,943
Education and awareness	1,601	1,273	-	458	667	3,999
Research	1,338	549	-	306	535	2,728
Total expenditure	11,917	31,807	75	4,067	5,855	53,721

2017/2018

Expenditure on:						
Raising funds						
Expenditure on raising donations and legacies	1,243	1,486	-	394	583	3,706
Expenditure on other trading activities	-	298	-	-	-	298
Charitable activities:						
Donor Provision	6,612	25,604	57	2,548	3,214	38,035
Education and awareness	1,373	608	-	373	565	2,919
Research	1,211	486	1,597	312	438	4,044
Total expenditure	10,439	28,482	1,654	3,627	4,800	49,002

Charity	Activities undertaken directly		Grant funding of activities	Support costs (note 10)		Total Costs
	Staff costs	Other costs		Staff costs	Other costs	
	£'000	£'000		£'000	£'000	
2018/2019						
Expenditure on:						
Raising funds	1,242	1,403	-	407	668	3,720
Charitable activities						
Donor Provision	7,736	28,251	75	2,896	3,985	42,943
Education and awareness	1,601	1,273	-	458	667	3,999
Research	1,338	549	-	306	535	2,728
Total expenditure	11,917	31,476	75	4,067	5,855	53,390

2017/2018

Expenditure on:						
Raising funds	1,243	1,486	-	394	583	3,706
Charitable activities						
Donor Provision	6,612	25,604	57	2,548	3,214	38,035
Education and awareness	1,373	608	-	373	565	2,919
Research	1,211	486	1,597	312	438	4,044
Total expenditure	10,439	28,184	1,654	3,627	4,800	48,704

The amount of irrecoverable VAT included in the group expenditure is £1,296k (2018: £1,064k).

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

9 ANALYSIS OF GRANTS	Grants to institutions £'000	Grants to individuals £'000	Support costs £'000	Total £'000
Group & Charity				
2018/2019				
Charitable activities:				
Donor Provision	5	70	15	90
Research	-	-	-	-
	5	70	15	90
2017/18				
Charitable activities:				
Donor Provision	16	41	12	69
Research	1,597	-	12	1,609
	1,613	41	24	1,678

During the 2018/19 financial year £5k (2018: £1,597k) worth of grants were given to institutions:

£2k (2018: Nil) was given to transplant centres for coordinators' visit to EBMT conference;

£1k (2018: Nil) was given to National BAME alliance;

£2k (2018: Nil) was given to your simPal.

During the 2018/19 financial year £70k (2018: £41k) worth of grants were given to individuals.

£53k (2018: £27k) was given to 246 (2018: 158) patients to help with the costs of lifestyle changes caused by treatment. £16k (2018: £14k) was given to 5 Marrow student and other support and recruitment groups.

10 ANALYSIS OF SUPPORT COSTS	Facilities £'000	Finance & Management £'000	Human Resources £'000	IT £'000	Governance £'000	Total £'000
Group & Charity						
2018/2019						
Expenditure on:						
Raising funds	199	162	119	543	52	1,075
Charitable activities:						
Donor Provision	1,162	1,522	692	3,175	330	6,881
Education and awareness	193	146	115	526	145	1,125
Research	160	105	96	438	42	841
Total support costs	1,714	1,935	1,022	4,682	569	9,922
2017/2018						
Expenditure on:						
Raising funds	236	157	121	420	43	977
Charitable activities:						
Donor Provision	1,254	1,360	643	2,238	267	5,762
Education and awareness	198	109	101	352	178	938
Research	175	141	90	312	32	750
Total support costs	1,863	1,767	955	3,322	520	8,427

Basis of the allocation of expenditure:

Where appropriate, expenditure, including depreciation, is allocated directly to the activity to which that expenditure relates.

Expenditure which does not relate directly to an activity but are incurred to enable activities to occur are classified as support costs.

- Finance & management costs relating to governance are estimated based on the time and resources incurred on governance activities.

- Other finance costs are apportioned in proportion to total direct expenditure incurred per activity.

- All other support costs are apportioned in accordance with the average full time equivalent number of staff directly employed in that activity during the financial year.

During 2018/19 £199k (2017/18: £252k) was expended to update processes and procedures to comply with General Data Protection Regulation (GDPR). These costs form part of the Governance costs.

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

11 STAFF COSTS

The charity considers its key management personnel, as defined by FRS 102, to comprise the Trustees, the Chief Executive Officer and the members of its Strategic Leadership Team. All Trustees give their time freely and no one receives remuneration.

	Group and Charity 2019 No.	Group and Charity 2018 No.
The average monthly number of persons employed by the group during the year (excluding trustees) was:		
Charitable activities:		
Donor provision	240	214
Education and awareness	33	31
Research	26	27
Raising funds	34	34
	333	306
	£'000	£'000
Staff costs for the above:		
Wages and salaries	11,961	10,771
Social security costs	1,242	1,142
Pension costs	566	360
Staff restructuring costs	40	34
	13,809	12,307
	£'000	£'000
Staff costs are allocated in the group's financial statements as follows:		
Donor provision	10,632	9,160
Education and awareness	2,059	1,746
Research	1,644	1,523
Raising funds	1,649	1,637
	15,984	14,066

Included in the allocated staff costs (note 8), in addition to payroll costs are the costs of funding academic positions of £99k (2018: £93k); staff benefit costs of £90k (2018: £110k); NHS secondment and other similar costs of £1,897k (2018: £1,446k) and £89k (2018: £109k) other staff costs including training and staff holiday accrual.

Remuneration and benefits received in the year by key management personnel, including employer's National Insurance contributions, were £1,004k (2018: £973k).

	Group and Charity 2019 No.	Group and Charity 2018 No.
The number of employees whose emoluments for the year fell within the following ranges was:		
£60,001 to £70,000	5	4
£70,001 to £80,000	4	1
£80,001 to £90,000	2	3
£90,001 to £100,000	1	2
£100,001 to £110,000	1	1
£120,001 to £130,000	1	1
£130,001 to £140,000	1	1

The group made contributions to money purchase pension schemes on behalf of all employees whose emoluments exceeded £60,000, and the total contributions payable during the year amounted to £68k (2018: £67k).

Amount of travel expenses claimed by one Trustee was £422 (2018: £298).

ANTHONY NOLAN & SUBSIDIARY UNDERTAKING

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

12 OTHER COSTS	2019	2018
	£'000	£'000
Net movement in funds is stated after charging:		
Depreciation and amounts written off fixed assets:		
Charge for the year	1,138	1,231
Impairment loss and write offs	1,138	1,218
Stock: amounts expensed during the year	-	13
Research and development expenditure	2,381	2,466
Operating lease rentals:		
Land and buildings	1,887	3,294
Plant and machinery	459	442
Auditor's remuneration:	4	3
Statutory Audit fees payable to		
RSM UK Audit LLP (Charity £34k (2018: £33k))	44	43
Tax Services payable to		
RSM UK Tax & Accounting Ltd:		
Tax compliance	5	5
Advisory	15	-

The group and the charity have an insurance policy that provides professional indemnity insurance cover for the trustees. The cost of this insurance for the year was £3k (2018: £3k).

During the year to 31 March 2019, the group accounted for net foreign exchange gains of £18k (2018: £15k net gains).

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

13 TANGIBLE ASSETS

	Leasehold buildings		Leasehold improvements, fixtures & fittings	Office equipment	Laboratory equipment	TOTAL
	Long term £'000	Short term £'000	£'000	£'000	£'000	£'000
Group & Charity						
Cost:						
1 April 2018	1,842	137	1,131	3,144	4,774	11,028
Additions	-	-	122	168	159	449
31 March 2019	1,842	137	1,253	3,312	4,933	11,477
Depreciation and impairment:						
1 April 2018	583	70	1,001	2,180	3,701	7,535
Charge for the year	16	6	84	433	599	1,138
31 March 2019	599	76	1,085	2,613	4,300	8,673
Net book value:						
31 March 2019	1,243	61	168	699	633	2,804
31 March 2018	1,259	67	130	964	1,073	3,493

Certain leasehold buildings are used, when surplus to the group's and the charity's requirements, to generate rental income under operating leases.

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

14 INVESTMENTS	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
Funds held in managed portfolios				
Valuation at 1 April	-	-	-	-
Acquisition at cost	3,000	-	3,000	-
Income received	21	-	21	-
Net gains on revaluation	78	-	78	-
Investment management costs	(6)	-	(6)	-
Valuation at 31 March	<u>3,093</u>	<u>-</u>	<u>3,093</u>	<u>-</u>

The historical cost of the share portfolio is £3m (2018: Nil). There are no holdings over 5% of the portfolio value.
 All of the investment portfolio is in listed investments, apart from £170k, which is cash.

ANTHONY NOLAN & SUBSIDIARY UNDERTAKING

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

15 STOCKS	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
Raw materials and consumables	574	553	574	553

16 DEBTORS	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
Amounts falling due within one year:				
Trade debtors	7,743	6,802	7,714	6,792
Amounts due from group undertakings	-	-	432	193
Gift Aid distribution receivable from group undertakings	-	-	104	60
Other debtors	134	127	134	127
Prepayments and accrued income	2,448	2,077	2,364	2,020
	10,325	9,006	10,748	9,192

17 CASH	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
Cash at bank and in hand	7,755	10,166	7,068	9,773

18 CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
Trade creditors	3,416	3,693	3,361	3,646
Other creditors	70	55	70	55
Other taxation and social security costs	334	306	334	306
Accruals and deferred income	4,258	2,762	4,109	2,662
Grants payable	685	493	685	493
	8,763	7,309	8,559	7,162

The Charity is party to a Group VAT registration with other companies of the Group of which it is a member. At 31 March 2019 the amount due under this arrangement in respect of all Group companies was £12k (2018: £4k).

19 CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
Grants payable	806	999	806	999

20 GRANTS PAYABLE	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
Grants brought forward	1,492	-	1,492	-
Additions	89	1,654	89	1,654
Payments	(90)	(162)	(90)	(162)
Grants carried forward				
Payable within one year	685	493	685	493
Payable after more than one year	806	999	806	999
	1,491	1,492	1,491	1,492

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

21 MOVEMENTS IN DEFERRED INCOME	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
Deferred income at beginning of the year	442	471	364	344
Income recognised in the year	(435)	(464)	(357)	(337)
Income deferred in the current year	537	435	399	357
Deferred income at the year end	<u>544</u>	<u>442</u>	<u>406</u>	<u>364</u>

Deferred income comprises income received in respect of the future fundraising events.

22 PROVISIONS FOR LIABILITIES & CHARGES	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
Provision for dilapidations	<u>568</u>	<u>568</u>	<u>568</u>	<u>568</u>

A provision for dilapidations is being carried in the balance sheets of the group and the charity in respect of the estimated costs of unavoidable reinstatement and refurbishment works relating to certain leasehold properties that are currently occupied by the charity for its own use. This provision was created in 2004, added to in 2017 (£200k) and is now expected to be utilised at the earliest in 2021.

23 FINANCIAL INSTRUMENTS	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
Carrying amount of financial assets				
Financial assets at fair value through income or expenditure	3,093	-	3,093	-
Debt instruments measured at amortised cost	<u>9,122</u>	<u>7,942</u>	<u>9,615</u>	<u>8,285</u>
Carrying amount of financial liabilities				
Measured at amortised cost	<u>8,691</u>	<u>7,531</u>	<u>8,625</u>	<u>7,463</u>

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 March 2019

24 THE FUNDS OF THE GROUP & THE CHARITY	Balance at 1 Apr 2018 £'000	Incoming resources £'000	Outgoing resources £'000	Gross transfers between funds £'000	Net gains on investments £'000	Balance at 31 Mar 2019 £'000
Group						
Restricted income funds						
<u>Voluntary and statutory income</u>						
Donor Campaign and Processing Fund	88	103	(88)	-	-	103
Donor Provision Fund	139	98	(236)	-	-	1
Research Projects Fund	2	30	(2)	(21)	-	9
Laboratory Equipment Fund	28	40	(10)	(45)	-	13
Patient Experience Fund	62	49	(62)	-	-	49
	319	320	(398)	(66)	-	175
Scientific Research Funds	370	216	(192)	-	-	394
	689	536	(590)	(66)	-	569
Unrestricted income funds						
<u>Designated funds</u>						
Property Fund	500	-	-	(500)	-	-
Digital & Technology Fund	98	-	(98)	500	-	500
Raising Awareness Fund	350	-	(350)	-	-	-
Register Enrichment Fund	186	-	(186)	-	-	-
Innovation Fund	300	-	-	-	-	300
	1,434	-	(634)	-	-	800
General Fund	12,219	53,179	(52,497)	66	78	13,045
Total funds	14,342	53,715	(53,721)	-	78	14,414
Charity						
Restricted income funds						
<u>Voluntary and statutory income</u>						
Donor Campaign and Processing Fund	88	103	(88)	-	-	103
Donor Provision Fund	139	98	(236)	-	-	1
Research Projects Fund	2	30	(2)	(21)	-	9
Laboratory Equipment Fund	28	40	(10)	(45)	-	13
Patient Experience Fund	62	49	(62)	-	-	49
	319	320	(398)	(66)	-	175
Scientific Research Funds	370	216	(192)	-	-	394
	689	536	(590)	(66)	-	569
Unrestricted income funds						
<u>Designated funds</u>						
Property Fund	500	-	-	(500)	-	-
Digital & Technology Fund	98	-	(98)	500	-	500
Raising Awareness Fund	350	-	(350)	-	-	-
Register Enrichment Fund	186	-	(186)	-	-	-
Innovation Fund	300	-	-	-	-	300
	1,434	-	(634)	-	-	800
General Fund	12,159	52,848	(52,166)	66	78	12,985
Total funds	14,282	53,384	(53,390)	-	78	14,354

Restricted funds

Donor Campaign and Processing Fund: in 2018/2019 the charity received various grants for the purposes of Register to Be a Lifesaver campaign.

Donor Provision Fund: in 2018/2019 the charity received various grants to recruit and type to high resolution male donors aged between 16 and 30 years.

Donations and grants received to fund the purchase of specific items of laboratory equipment for either research or histocompatibility laboratories are credited to the **Laboratory Equipment Fund**. When the specified asset is purchased and there is no on-going restriction over its use, the value of the asset is transferred to General Fund. £66k was transferred from Laboratory Equipment Fund to General Fund.

The depreciation of the asset is charged to the General Fund over the life of the asset.

Patient Experience Fund was created in 2014/15 for the purposes of supporting post transplant patients. 2018/19 grants were mainly to fund positions of patient nurses in UK Transplant Centres and support patients' grant scheme.

The Scientific Research Fund and the **Research Projects Fund** are set up to recognise income received annually in the form of a number of different grants awarded for specific research projects in immunogenetics and related fields. The cost of undertaking these research projects is allocated to the funds, with unspent monies being carried forward into 2019/2020.

Funds are designated for the following purposes:

Property Fund: for future expenditure in property. £500k brought forward from 2017/18 was re-designated to the Digital & Technology Fund.

Digital & Technology Fund: to invest in digital and technology to deliver the greater patient benefits. £500k was re-designated to the Fund from the Property fund for the purposes of software and other technology development, including a new CRM system. The fund is expected to be utilised within the next 12-18 months.

Raising Awareness Fund: to invest in brand awareness. £350k brought forward from 2017/18 was fully utilised during this financial year.

Register Enrichment Fund: to type more donors at a higher resolution for patient benefit. £186k brought forward from 2017/18 was fully utilised during this financial year.

Innovation Fund: to fund new income generating initiatives and public awareness. The fund is expected to be fully utilised during 2019/20 financial year.

	Fixed assets £'000	Net current assets £'000	Creditors over 1 year and provisions for liabilities and charges £'000	Total £'000
25 ANALYSIS OF NET ASSETS BETWEEN FUNDS				
Group				
Restricted income funds	-	569	-	569
Unrestricted income funds: General Fund	5,897	9,322	(1,374)	13,845
NET ASSETS	5,897	9,891	(1,374)	14,414
Charity				
Restricted income funds	-	569	-	569
Unrestricted income funds: General Funds	5,897	9,262	(1,374)	13,785
NET ASSETS	5,897	9,831	(1,374)	14,354

	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
26 COMMITMENTS UNDER OPERATING LEASES				

The Charity as a lessee:

The total future minimum lease payments under non-cancellable operating leases, which are calculated based on rent notice period, are as follows:

Land and buildings				
Amounts due				
Within one year	433	323	433	323
Between one and five years	14	14	14	14
Plant and machinery				
Amounts due				
Within one year	8	17	8	17
Between one and five years	-	8	-	8
	455	362	455	362

The total future minimum service charge payments are as follows:

Land and buildings				
Amounts due				
Within one year	217	223	217	223
Between one and five years	164	164	164	164
	381	387	381	387

The Charity as lessor:

At the year end, the Charity had contracted with tenants, under non-cancellable operating leases, for the following future minimum lease payments:

Amounts receivable:				
Less than one year	75	75	75	75
	75	75	75	75

The operating leases represent lease of 65% of Research facility to a third party. The lease is negotiated over terms of 77 years (2018: 78 years) and rentals are fixed for 2 years and 3 months (2018: 3 years and 3 months).

27 PENSION COMMITMENTS

The group and the charity make contributions into defined contribution pension schemes on behalf of certain employees. The assets of the schemes are held separately from those of the group and the charity in independently administered funds. The amount charged to the Statement of Financial Activities in respect of pension costs (as shown in note 11) is the total contributions payable for the period. The amount payable at 31 March 2019 is £69k, (2018: £55k).

	Group 2019 £'000	Group 2018 £'000	Charity 2019 £'000	Charity 2018 £'000
28 CAPITAL COMMITMENTS				
Capital commitments - contracted for, but not provided	-	122	-	122

ANTHONY NOLAN & SUBSIDIARY UNDERTAKING

NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 March 2019

29 RELATED PARTIES TRANSACTIONS

Anthony Nolan Trading Limited (ANTL) is a wholly owned subsidiary of Anthony Nolan.

During 2018/19 Anthony Nolan received £200k worth of income from ANTL, which is made up of Gift Aid £104k and management charge £96k (2017/18 income of £149k: Gift Aid £60k and management charge £89k).

The nature of transfers to/from the subsidiary covers the following areas:

- Income received by the Charity on behalf of ANTL;
- Income received by ANTL on behalf of the Charity;
- Expenditure incurred by the Charity on behalf of ANTL

ANTL debtor balance at 31 March 2019 was £536k (31 March 2018: £252k).